{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# LLM Agents for Clinical Trial Management\n",
    "\n",
    "In this notebook, we develop an agent-based Large Language Model (LLM) application to automate the evaluation of patients for potential clinical trials. By leveraging documents related to patients' medical histories, clinical policies, and trial inclusion criteria, such an agentic system can significantly enhance the quality of evaluations and reduce the time required.\n",
    "\n",
    "We use limited demo databases and simple agentic tools and pipelines to demonstrate the capabilities of such LLM systems. For real-world applications, more comprehensive medical databases, in collaboration with clinical specialists, will be necessary. Additionally, more advanced tools (e.g., advanced Retrieval-Augmented Generation (RAG) methods) must be incorporated for real applications.\n",
    "\n",
    "**Objective:** Automate clinical trial data management, analysis, compliance checks, and reporting.\n",
    "\n",
    "## Key Components of This Design: \n",
    "1. Patient Data Collection: Gather comprehensive medical histories and relevant patient information.\n",
    "2. Patient Data Analysis: Analyze patient data to identify key health indicators and relevant medical conditions.\n",
    "3. Clinical Compliance Verification: Ensure patient data complies with clinical policies and trial eligibility criteria.\n",
    "4. Trial Matching: Match patients with suitable clinical trials based on their medical profiles.\n",
    "5. Human-in-the-Loop Interventions: Allow clinical experts to review and modify intermediate and final outcomes.\n",
    "\n",
    "## Technologies and Tools Used:\n",
    "- Local Models: Embedding of policies and trial information.\n",
    "- Local Vector Stores: Information retrieval using metadata.\n",
    "- Information Retrieval: Using metadata to find relevant documents.\n",
    "- Chains of LLM Calls: Sequential LLM calls to perform complex tasks.\n",
    "- Python Shell: LLM integration for performing numerical calculations.\n",
    "- Agentic Graph: Deploying a workflow for evaluating patients and trials.\n",
    "- Human-in-the-Loop: Clinical experts can intervene and modify the evaluation process and results."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import getpass\n",
    "import os\n",
    "\n",
    "\n",
    "def _set_if_undefined(var: str):\n",
    "    if not os.environ.get(var):\n",
    "        os.environ[var] = getpass.getpass(f\"Please provide your {var}\")\n",
    "\n",
    "# Loading the requied environment variables\n",
    "_set_if_undefined(\"OPENAI_API_KEY\")\n",
    "_set_if_undefined(\"LANGCHAIN_API_KEY\")\n",
    "\n",
    "# Optional, add tracing in LangSmith\n",
    "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
    "os.environ[\"LANGCHAIN_PROJECT\"] = \"Clinical Trial Management\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Parameters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "\n",
    "policy_vstore_created = False\n",
    "trials_vstore_created = False\n",
    "trials_db_downloaded = False\n",
    "chromadb_path = \"../../chroma_db\"\n",
    "policy_collection = \"policy-chroma\"\n",
    "trial_collection = \"trial-chroma\"\n",
    "\n",
    "modelID = \"gpt-3.5-turbo\"\n",
    "n_retrieved_policies = 5 # Number of most relevant policies to retrieve per patient\n",
    "# n_retries = 6\n",
    "n_retrieved_trials = 6\n",
    "\n",
    "\n",
    "\n",
    "model = ChatOpenAI(temperature = 0.0, model=modelID)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "import pprint\n",
    "# A function for printing nicely\n",
    "def nprint(text, indent=2):\n",
    "    pp = pprint.PrettyPrinter(indent=indent)\n",
    "    pp.pprint(text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating the demo datasets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patients database\n",
    "\n",
    "We create a sample dataset of patients with their medical history, previous trials, and other relevant information.   \n",
    "We use random names, diseases, and past or ongoing trials.  \n",
    "This is a demo dataset limited information. However, for real cases, a more complit medical history of patients will be used."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Jane Anderson</td>\n",
       "      <td>48</td>\n",
       "      <td>Obesity</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Alice Brown</td>\n",
       "      <td>40</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>NCT05724456</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-11-18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Alice Wilson</td>\n",
       "      <td>51</td>\n",
       "      <td>peritoneal cancer</td>\n",
       "      <td>NCT07030148</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-11-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>James Martinez</td>\n",
       "      <td>72</td>\n",
       "      <td>gastric cancer</td>\n",
       "      <td>NCT06745637</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-08-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Michael Wilson</td>\n",
       "      <td>66</td>\n",
       "      <td>pancreatic cancer</td>\n",
       "      <td>NCT06410934</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2022-07-26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Jane Doe</td>\n",
       "      <td>72</td>\n",
       "      <td>myeloma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Emma Brown</td>\n",
       "      <td>56</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Michael Thomas</td>\n",
       "      <td>28</td>\n",
       "      <td>lung cancer</td>\n",
       "      <td>NCT04356469</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Oliver Wilson</td>\n",
       "      <td>33</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Emma Wilson</td>\n",
       "      <td>79</td>\n",
       "      <td>leiomyosarcoma</td>\n",
       "      <td>NCT06400191</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-06-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Jane Davis</td>\n",
       "      <td>77</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Alice Anderson</td>\n",
       "      <td>30</td>\n",
       "      <td>Depression</td>\n",
       "      <td>NCT02162187</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>James Brown</td>\n",
       "      <td>76</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>NCT09663477</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>James Brown</td>\n",
       "      <td>35</td>\n",
       "      <td>esophageal cancer</td>\n",
       "      <td>NCT01668174</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-09-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>John Brown</td>\n",
       "      <td>60</td>\n",
       "      <td>Chronic Pain</td>\n",
       "      <td>NCT08518122</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-09-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Michael Wilson</td>\n",
       "      <td>38</td>\n",
       "      <td>myeloid leukemia</td>\n",
       "      <td>NCT08320893</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Oliver Brown</td>\n",
       "      <td>71</td>\n",
       "      <td>mesothelioma</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Sophia Anderson</td>\n",
       "      <td>80</td>\n",
       "      <td>lymphoblastic leukemia</td>\n",
       "      <td>NCT09389201</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2024-06-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Oliver Garcia</td>\n",
       "      <td>58</td>\n",
       "      <td>gastric cancer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Alice Davis</td>\n",
       "      <td>74</td>\n",
       "      <td>myelomonocytic leukemia</td>\n",
       "      <td>NCT02343759</td>\n",
       "      <td>Ongoing</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    patient_id             name  age          medical_history previous_trials  \\\n",
       "0            1    Jane Anderson   48                  Obesity                   \n",
       "1            2      Alice Brown   40                 Diabetes     NCT05724456   \n",
       "2            3     Alice Wilson   51        peritoneal cancer     NCT07030148   \n",
       "3            4   James Martinez   72           gastric cancer     NCT06745637   \n",
       "4            5   Michael Wilson   66        pancreatic cancer     NCT06410934   \n",
       "5            6         Jane Doe   72                  myeloma                   \n",
       "6            7       Emma Brown   56          prostate cancer                   \n",
       "7            8   Michael Thomas   28              lung cancer     NCT04356469   \n",
       "8            9    Oliver Wilson   33  myelomonocytic leukemia                   \n",
       "9           10      Emma Wilson   79           leiomyosarcoma     NCT06400191   \n",
       "10          11       Jane Davis   77             Chronic Pain                   \n",
       "11          12   Alice Anderson   30               Depression     NCT02162187   \n",
       "12          13      James Brown   76          prostate cancer     NCT09663477   \n",
       "13          14      James Brown   35        esophageal cancer     NCT01668174   \n",
       "14          15       John Brown   60             Chronic Pain     NCT08518122   \n",
       "15          16   Michael Wilson   38         myeloid leukemia     NCT08320893   \n",
       "16          17     Oliver Brown   71             mesothelioma                   \n",
       "17          18  Sophia Anderson   80   lymphoblastic leukemia     NCT09389201   \n",
       "18          19    Oliver Garcia   58           gastric cancer                   \n",
       "19          20      Alice Davis   74  myelomonocytic leukemia     NCT02343759   \n",
       "\n",
       "   trial_status trial_completion_date  \n",
       "0                                      \n",
       "1     Withdrawn            2023-11-18  \n",
       "2     Withdrawn            2023-11-30  \n",
       "3     Completed            2023-08-09  \n",
       "4     Completed            2022-07-26  \n",
       "5                                      \n",
       "6                                      \n",
       "7       Ongoing                        \n",
       "8                                      \n",
       "9     Completed            2023-06-08  \n",
       "10                                     \n",
       "11      Ongoing                        \n",
       "12      Ongoing                        \n",
       "13    Completed            2023-09-06  \n",
       "14    Withdrawn            2022-09-05  \n",
       "15      Ongoing                        \n",
       "16                                     \n",
       "17    Completed            2024-06-12  \n",
       "18                                     \n",
       "19      Ongoing                        "
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from datetime import datetime, timedelta\n",
    "import numpy as np\n",
    "import json\n",
    "import random\n",
    "\n",
    "# Generate the sample data again for display\n",
    "columns = [\"patient_id\", \"name\", \"age\", \"medical_history\", \"previous_trials\", \"trial_status\", \"trial_completion_date\"]\n",
    "data = []\n",
    "\n",
    "# Given names and surnames\n",
    "names = [\"John\", \"Jane\", \"Alice\", \"Michael\", \"Emily\", \"Daniel\", \"Sophia\", \"James\", \"Emma\", \"Oliver\"]\n",
    "surnames = [\"Doe\", \"Smith\", \"Johnson\", \"Brown\", \"Davis\", \"Garcia\", \"Martinez\", \"Anderson\", \"Thomas\", \"Wilson\"]\n",
    "\n",
    "# Generate all possible unique combinations of names and surnames\n",
    "combinations = [(name, surname) for name in names for surname in surnames]\n",
    "\n",
    "# Shuffle the combinations to ensure randomness\n",
    "random.shuffle(combinations)\n",
    "\n",
    "# Select the first 100 unique combinations\n",
    "unique_names = combinations[:100]\n",
    "\n",
    "# Generate the full names\n",
    "full_names = [f\"{name} {surname}\" for name, surname in unique_names]\n",
    "\n",
    "with open('../../source_data/diseases_list.json', 'r') as file:\n",
    "        trial_diseases =  json.load(file)\n",
    "\n",
    "list_trial_diseases = list({disease for diseases in trial_diseases.values() for disease in diseases})\n",
    "\n",
    "other_medical_conditions = [\"Hypertension\", \"Diabetes\", \"Asthma\", \"Heart Disease\", \"Arthritis\",\n",
    "                      \"Chronic Pain\", \"Anxiety\", \"Depression\", \"Obesity\"]\n",
    "\n",
    "all_conditions = list(set(list_trial_diseases + other_medical_conditions))\n",
    "\n",
    "trial_statuses = [\"Completed\", \"Ongoing\", \"Withdrawn\"]\n",
    "\n",
    "def random_date(start, end):\n",
    "    return start + timedelta(days=random.randint(0, int((end - start).days)))\n",
    "\n",
    "# start_date must be 2 years before now\n",
    "start_date = datetime.now() - timedelta(days=365 * 2)\n",
    "# start_date = datetime(2020, 1, 1)\n",
    "\n",
    "# end_date must be a month before now\n",
    "end_date = datetime.now() - timedelta(days=10)\n",
    "# end_date = datetime(2023, 1, 1)\n",
    "\n",
    "for i in range(1, 101):\n",
    "    name = random.choice(full_names)\n",
    "    age = random.randint(20, 80)\n",
    "    medical_history = random.choice(all_conditions)\n",
    "    \n",
    "    if random.choice([True, False]):\n",
    "        previous_trials = f\"NCT0{random.randint(1000000, 9999999)}\"\n",
    "        trial_status = random.choice(trial_statuses)\n",
    "        trial_completion_date = random_date(start_date, end_date).strftime('%Y-%m-%d')\n",
    "    else:\n",
    "        previous_trials = \"\"\n",
    "        trial_status = \"\"\n",
    "        trial_completion_date = \"\"\n",
    "    if trial_status == \"Ongoing\":\n",
    "        trial_completion_date = \"\"\n",
    "\n",
    "    data.append((i, name, age, medical_history, previous_trials, trial_status, trial_completion_date))\n",
    "\n",
    "df = pd.DataFrame(data, columns=columns)\n",
    "# save df to csv\n",
    "df.to_csv(\"patients.csv\", index=False)\n",
    "df.head(20)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Creating a local SQLite database for patients"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>James Anderson</td>\n",
       "      <td>75</td>\n",
       "      <td>Heart Disease</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Emily Martinez</td>\n",
       "      <td>73</td>\n",
       "      <td>esophageal cancer</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Alice Thomas</td>\n",
       "      <td>24</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Alice Garcia</td>\n",
       "      <td>39</td>\n",
       "      <td>solid tumors</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>John Davis</td>\n",
       "      <td>40</td>\n",
       "      <td>Hypertension</td>\n",
       "      <td>NCT09100764</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2023-10-24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>John Garcia</td>\n",
       "      <td>45</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>NCT04864147</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2022-08-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Michael Smith</td>\n",
       "      <td>64</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NCT08217147</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-02-18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Oliver Thomas</td>\n",
       "      <td>25</td>\n",
       "      <td>solid tumors</td>\n",
       "      <td>NCT06705148</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-06-23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Emily Martinez</td>\n",
       "      <td>27</td>\n",
       "      <td>ovarian cancer</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Emma Brown</td>\n",
       "      <td>26</td>\n",
       "      <td>mesothelioma</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   patient_id            name  age    medical_history previous_trials  \\\n",
       "0           1  James Anderson   75      Heart Disease            None   \n",
       "1           2  Emily Martinez   73  esophageal cancer            None   \n",
       "2           3    Alice Thomas   24    prostate cancer            None   \n",
       "3           4    Alice Garcia   39       solid tumors            None   \n",
       "4           5      John Davis   40       Hypertension     NCT09100764   \n",
       "5           6     John Garcia   45             Asthma     NCT04864147   \n",
       "6           7   Michael Smith   64            Obesity     NCT08217147   \n",
       "7           8   Oliver Thomas   25       solid tumors     NCT06705148   \n",
       "8           9  Emily Martinez   27     ovarian cancer            None   \n",
       "9          10      Emma Brown   26       mesothelioma            None   \n",
       "\n",
       "  trial_status trial_completion_date  \n",
       "0         None                  None  \n",
       "1         None                  None  \n",
       "2         None                  None  \n",
       "3         None                  None  \n",
       "4    Withdrawn            2023-10-24  \n",
       "5    Withdrawn            2022-08-12  \n",
       "6    Withdrawn            2024-02-18  \n",
       "7    Completed            2023-06-23  \n",
       "8         None                  None  \n",
       "9         None                  None  "
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import os\n",
    "import sqlite3\n",
    "import pandas as pd\n",
    "\n",
    "overwrite = True\n",
    "\n",
    "database_file = 'patients_database.db'\n",
    "df = pd.read_csv('patients.csv')\n",
    "if overwrite or not os.path.exists(database_file):\n",
    "    if os.path.exists(database_file):\n",
    "        os.remove(database_file)\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "    cursor.execute('''\n",
    "    CREATE TABLE IF NOT EXISTS patients (\n",
    "        patient_id INTEGER PRIMARY KEY,\n",
    "        name TEXT,\n",
    "        age INTEGER,\n",
    "        medical_history TEXT,\n",
    "        previous_trials TEXT,\n",
    "        trial_status TEXT,\n",
    "        trial_completion_date TEXT\n",
    "    )\n",
    "    ''')\n",
    "\n",
    "    # Insert DataFrame into SQLite table\n",
    "    df.to_sql('patients', conn, if_exists='append', index=False)\n",
    "\n",
    "    # Commit and close the connection\n",
    "    conn.commit()\n",
    "else:\n",
    "    conn = sqlite3.connect(database_file)\n",
    "    cursor = conn.cursor()\n",
    "\n",
    "query = 'SELECT * FROM patients'\n",
    "\n",
    "# Execute the query and fetch all results\n",
    "cursor.execute(query)\n",
    "rows = cursor.fetchall()\n",
    "\n",
    "# Optionally, you can get the column names\n",
    "column_names = [description[0] for description in cursor.description]\n",
    "\n",
    "# Convert the results to a Pandas DataFrame for better readability\n",
    "df = pd.DataFrame(rows, columns=column_names)\n",
    "print(len(df))\n",
    "\n",
    "# Display the DataFrame\n",
    "conn.close()\n",
    "\n",
    "db = database_file\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>patient_id</th>\n",
       "      <th>name</th>\n",
       "      <th>age</th>\n",
       "      <th>medical_history</th>\n",
       "      <th>previous_trials</th>\n",
       "      <th>trial_status</th>\n",
       "      <th>trial_completion_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Michael Smith</td>\n",
       "      <td>64</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NCT08217147</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>2024-02-18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Emma Martinez</td>\n",
       "      <td>35</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Michael Brown</td>\n",
       "      <td>76</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NCT07416735</td>\n",
       "      <td>Completed</td>\n",
       "      <td>2023-11-18</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    patient_id           name  age medical_history previous_trials  \\\n",
       "6            7  Michael Smith   64         Obesity     NCT08217147   \n",
       "14          15  Emma Martinez   35         Obesity            None   \n",
       "35          36  Michael Brown   76         Obesity     NCT07416735   \n",
       "\n",
       "   trial_status trial_completion_date  \n",
       "6     Withdrawn            2024-02-18  \n",
       "14         None                  None  \n",
       "35    Completed            2023-11-18  "
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['medical_history'].str.contains('Obes')]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clinical Trials database\n",
    "\n",
    "We download a sample clinical trials database from a [publicly available source]('https://raw.githubusercontent.com/futianfan/clinical-trial-outcome-prediction/main/data/raw_data.csv').   \n",
    "Details are provided in the [helper function](../../src/helper_functions.py)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Only trials with status recruiting are selected.\n",
      "The database for trials is saved to ../../data/trials_data.csv \n",
      " It has 30 rows.\n",
      "---- Sample 1 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Newly diagnosed adult B-precursor Ph+ ALL patients.\n",
      "\n",
      "          -  Age greater or equal to18 years,\n",
      "\n",
      "          -  Signed written informed consent according to ICH/EU/GCP and national local laws.\n",
      "\n",
      "          -  ECOG Performance Status 0 or 1 and/or WHO performance status less or equal to 2.\n",
      "\n",
      "          -  Renal and hepatic function as defined below:\n",
      "\n",
      "               -  AST (GOT), ALT (GPT), and AP <2 x upper limit of normal (ULN).\n",
      "\n",
      "               -  Total bilirubin <1.5 x ULN.\n",
      "\n",
      "               -  Creatinine clearance equal or greater than 50 mL/min.\n",
      "\n",
      "          -  Pancreatic function as defined below:\n",
      "\n",
      "               -  Serum amylase less or equal to 1.5 x ULN\n",
      "\n",
      "               -  Serum lipase less or equal to1.5 x ULN.\n",
      "\n",
      "          -  Normal cardiac function.\n",
      "\n",
      "          -  Negative HIV test, negative HBV DNA and HCV RNA.\n",
      "\n",
      "          -  Negative pregnancy test in women of childbearing potential.\n",
      "\n",
      "          -  Bone marrow specimen from primary diagnosis available.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  History of or current relevant CNS pathology (current ≥grade 2 epilepsy, seizure,\n",
      "             paresis, aphasia, clinically relevant apoplexia, severe brain injuries, dementia,\n",
      "             Parkinson's disease, organic brain syndrome, psychosis).\n",
      "\n",
      "          -  Impaired cardiac function, including any one of the following:\n",
      "\n",
      "               -  LVEF <45% as determined by MUGA scan or echocardiogram.\n",
      "\n",
      "               -  Complete left bundle branch block.\n",
      "\n",
      "               -  Use of a cardiac pacemaker.\n",
      "\n",
      "               -  ST depression of >1mm in 2 or more leads and/or T wave inversions in 2 or more\n",
      "                  contiguous leads.\n",
      "\n",
      "               -  Congenital long QT syndrome.\n",
      "\n",
      "               -  History of or presence of significant ventricular or atrial arrhythmia.\n",
      "\n",
      "               -  Clinically significant resting bradycardia (<50 beats per minute).\n",
      "\n",
      "               -  QTc >450 msec on screening ECG (using the QTcF formula).\n",
      "\n",
      "               -  Right bundle branch block plus left anterior hemiblock, bifascicular block.\n",
      "\n",
      "               -  Myocardial infarction within 3 months prior to starting Dasatinib.\n",
      "\n",
      "               -  Angina pectoris.\n",
      "\n",
      "          -  Other clinically significant heart disease (e.g., congestive heart failure,\n",
      "             uncontrolled hypertension, history of labile hypertension, or history of poor\n",
      "             compliance with an antihypertensive regimen).\n",
      "\n",
      "          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly\n",
      "             alter the absorption of Dasatinib (e.g., ulcerative diseases, uncontrolled nausea,\n",
      "             vomiting, diarrhea, malabsorption syndrome, or small bowel resection).\n",
      "\n",
      "          -  History of or current autoimmune disease.\n",
      "\n",
      "          -  Systemic cancer chemotherapy within 2 weeks prior to study.\n",
      "\n",
      "          -  Known hypersensitivity to immunoglobulins or to any other component of the study drug\n",
      "             formulation.\n",
      "\n",
      "          -  Active malignancy other than ALL with the exception of basal cell or squamous cell\n",
      "             carcinoma of the skin, or carcinoma \"in situ\" of the cervix.\n",
      "\n",
      "          -  Active infection, any other concurrent disease or medical conditions that are deemed\n",
      "             to interfere with the conduct of the study as judged by the investigator.\n",
      "\n",
      "          -  Nursing women or women of childbearing potential not willing to use an effective form\n",
      "             of contraception during participation in the study and at least 3 months thereafter or\n",
      "             male patients not willing to ensure effective contraception during participation in\n",
      "             the study and at least three months thereafter.\n",
      "      \n",
      "---- Sample 2 ----\n",
      "\n",
      "        Cohort A: STS\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. The patient must sign voluntarily the informed consent form before any study test is\n",
      "             conducted that is not part of routine patient care.\n",
      "\n",
      "          2. Aged equal or over 18.\n",
      "\n",
      "          3. Patients must have a diagnostic of Soft Tissue Sarcoma with metastasis limited to\n",
      "             lung, and not suitable for metastasectomy or surgery resection or not oncologically\n",
      "             recommended metastasectomy.A centralized diagnostic will be performed, the tumor\n",
      "             sample must be available and sent prior to inclusion.\n",
      "\n",
      "          4. Disease distribution allows meeting with normal tissue constraints of radiation\n",
      "             therapy. Radiation oncologist must confirm this point.\n",
      "\n",
      "          5. Metastatic spread could be present in two organs at maximum (i.e. lungs and pelvic\n",
      "             fosa).\n",
      "\n",
      "          6. Those lesions considered for radiation therapy have to be considered as target lesions\n",
      "             as well. (i.e. in a patient with nodules in lungs, those lesions selected for\n",
      "             radiation therapy have to include at least the target lesions)\n",
      "\n",
      "          7. It is allowed that not all the lesions will be under radiation fields. As a general\n",
      "             rule, it will be prioritized to select, as target-irradiating lesions, those with\n",
      "             greater increase in size and those largest lesions. It should be discouraged to\n",
      "             irradiate pulmonary lesions with infiltration of pleural serosa.\n",
      "\n",
      "          8. Patients must have documentation of disease progression within 6 months prior to study\n",
      "             entry.\n",
      "\n",
      "          9. The patient must have been considered eligible for systemic chemotherapy. A maximum of\n",
      "             two previous lines for advanced/metastatic disease are allowed as long as trabectedin\n",
      "             has not been included.\n",
      "\n",
      "         10. The following histological subtypes can be included:\n",
      "\n",
      "             Undifferentiated pleomorphic sarcoma (previously, malignant fibrous histiocytoma)\n",
      "             Leiomyosarcoma Angiosarcoma/ epithelial hemangioendothelioma Liposarcoma and its\n",
      "             variants (well differentiated, dedifferentiated, myxoid/round cells, pleomorphic).\n",
      "\n",
      "             Synovial sarcoma Fibrosarcoma and its variants (epithelial fibrosarcoma/low grade\n",
      "             fibromyxoid sarcoma) Hemangiopericytoma/solitary fibroid tumor Neurogenic sarcoma\n",
      "             (Malignant peripheral nerve sheath tumor, MPNST) Myxofibrosarcoma Epithelioid Sarcoma\n",
      "             Unclassified sarcoma (spindle cell/epithelioid/pleomorphic/myxoid)\n",
      "\n",
      "         11. Measurable disease, according to RECIST V 1.1 criteria\n",
      "\n",
      "         12. Performance status ≤1 (ECOG).\n",
      "\n",
      "         13. Adequate respiratory functions: FEV1 >1L; DLco > 40% (patients with pulmonary target\n",
      "             lesions)\n",
      "\n",
      "         14. Adequate bone marrow function (hemoglobin > 10 g/dl, leukocytes ≥ 3.000/mm3,\n",
      "             neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤\n",
      "             1,6 mg/dl, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times\n",
      "             UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of\n",
      "             alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver\n",
      "             fraction and/or GGT must be ≤ UNL.\n",
      "\n",
      "         15. Men or women of child bearing potential should be using an effective method of\n",
      "             contraception before entry into the study and throughout the same and for 6 months\n",
      "             after ending the study. Women of childbearing potential must have a negative urine\n",
      "             pregnancy test before study entry.\n",
      "\n",
      "         16. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.\n",
      "\n",
      "         17. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive\n",
      "             it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If\n",
      "             these were positives the inclusion is not recommended, remaining at investigators'\n",
      "             discretion the preventive treatment with lamivudine. If a potential patient is\n",
      "             positive for anti-HCV antibodies, presence of the virus should be ruled out with a\n",
      "             qualitative PCR, or the patient should NOT be included in the study (if a qualitative\n",
      "             PCR cannot be performed then patient will not be able to enter the study)\n",
      "\n",
      "         18. Patient must have a Central Venous Catheter for treatment\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Previous treatment with trabectedin or previous treatment with radiotherapy (except if\n",
      "             previous radiotherapy treatment plus planned study radiotherapy treatment allow\n",
      "             tissues constrains)\n",
      "\n",
      "          2. Performance status ≥ 2 (ECOG).\n",
      "\n",
      "          3. Plasma bilirubin > UNL.\n",
      "\n",
      "          4. Creatinine > 1.6 mg/dL.\n",
      "\n",
      "          5. History of other neoplastic disease with less than 5 years free of disease with the\n",
      "             exception of basal cell carcinoma or in situ cervical cancer adequately treated.\n",
      "\n",
      "          6. Severe COPD or other severe pulmonary diseases.\n",
      "\n",
      "          7. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)\n",
      "\n",
      "          8. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that\n",
      "             limit patient availability, or according to investigator judgment may contribute\n",
      "             significantly to treatment toxicity.\n",
      "\n",
      "          9. Uncontrolled bacterial, mycotic or viral infections.\n",
      "\n",
      "         10. Known positive test for infection by human immunodeficiency virus (HIV).\n",
      "\n",
      "         11. Women who are pregnant or breast-feeding.\n",
      "\n",
      "         12. Psychological, familial, social or geographic circumstances that limit the patient\"s\n",
      "             ability to comply with the protocol or informed consent.\n",
      "\n",
      "         13. Patients participating in another clinical trial or receiving any other\n",
      "             investigational product\n",
      "\n",
      "         14. Patients who had participated in another clinical trial and/or had received any other\n",
      "             investigational product in the last 30 days prior to inclusion.\n",
      "\n",
      "         15. Histologies other than those described in inclusion criteria.\n",
      "\n",
      "        Cohort B: ML\n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          1. The patient must sign voluntarily the informed consent form before any study test is\n",
      "             conducted that is not part of routine patient care.\n",
      "\n",
      "          2. Age ≥18 years old.\n",
      "\n",
      "          3. Pathological diagnosis of Myxoid Liposarcoma, deep located and more than 5 cm or\n",
      "             superficial more than 10 cm. A centralized diagnostic will be performed to confirm\n",
      "             that the patient can be included in the study.\n",
      "\n",
      "          4. Tumor must be resectable and without evidence of regional or distal spread after\n",
      "             adequate staging procedure. Tumor must be located in limbs or superficial trunk wall.\n",
      "\n",
      "          5. Disease distribution allows meeting with normal tissue constraints of radiation\n",
      "             therapy. Radiation oncologist must confirm this point.\n",
      "\n",
      "          6. Measurable disease, according to RECIST V 1.1 criteria\n",
      "\n",
      "          7. Performance status 0-1 (ECOG).\n",
      "\n",
      "          8. Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes ≥ 3.000/mm3,\n",
      "             neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤\n",
      "             1,6 mg/dL, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times\n",
      "             UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of\n",
      "             alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver\n",
      "             fraction and/or GGT must be ≤ UNL.\n",
      "\n",
      "          9. Men or women of child bearing potential should be using an effective method of\n",
      "             contraception before entry into the study and throughout the same and for 6 months\n",
      "             after ending the study. Women of childbearing potential must have a negative urine\n",
      "             pregnancy test before study entry.\n",
      "\n",
      "         10. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.\n",
      "\n",
      "         11. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive\n",
      "             it is recommended to reject the existence of replicative phase (HbaAg+, DNA HBV+). If\n",
      "             these were positives the inclusion is not recommended, remaining at investigators'\n",
      "             discretion the preventive treatment with lamivudine. If a potential patient is\n",
      "             positive for anti-HCV antibodies, presence of the virus should be ruled out with a\n",
      "             qualitative PCR, or the patient should NOT be included in the study (if a qualitative\n",
      "             PCR cannot be performed then patient will not be able to enter the study).\n",
      "\n",
      "         12. Patient may have had one previous chemotherapy line.\n",
      "\n",
      "         13. Patient must have a Central Venous Catheter for treatment.\n",
      "\n",
      "        Exclusion criteria:\n",
      "\n",
      "          1. Unresectable tumors (with limb sparing surgery)\n",
      "\n",
      "          2. More than one previous chemotherapy treatment for local disease including trabectedin.\n",
      "\n",
      "          3. Radiotherapy involving the tumoral bed.\n",
      "\n",
      "          4. Performance status ≥ 2 (ECOG).\n",
      "\n",
      "          5. Presence of metastases or lymph node involvement by the tumor.\n",
      "\n",
      "          6. Location other than limb or superficial trunk wall.\n",
      "\n",
      "          7. Plasma bilirubin > UNL.\n",
      "\n",
      "          8. Creatinine > 1.6 mg/dL.\n",
      "\n",
      "          9. History of other neoplastic disease with less than 5 years free of disease with the\n",
      "             exception of basal cell carcinoma or in situ cervical cancer adequately treated.\n",
      "\n",
      "         10. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)\n",
      "\n",
      "         11. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that\n",
      "             limit patient availability, or according to investigator judgment may contribute\n",
      "             significantly to treatment toxicity.\n",
      "\n",
      "         12. Uncontrolled bacterial, mycotic or viral infections.\n",
      "\n",
      "         13. Known positive test for infection by human immunodeficiency virus (HIV).\n",
      "\n",
      "         14. Women who are pregnant or breast-feeding.\n",
      "\n",
      "         15. Psychological, familial, social or geographic circumstances that limit the patient\"s\n",
      "             ability to comply with the protocol or informed consent.\n",
      "\n",
      "         16. Patients who had participated in another clinical trial and/or had received any other\n",
      "             investigational product in the last 30 days prior to inclusion.\n",
      "\n",
      "        Cohort C: Retroperitoneum sarcoma\n",
      "\n",
      "        Inclusion criteria:\n",
      "\n",
      "          1. The patient must voluntarily sign the informed consent form before performing any\n",
      "             study-specific test that is not part of the patient's usual care.\n",
      "\n",
      "          2. Aged between 18 and 75 years.\n",
      "\n",
      "          3. The following histological subtypes may be included: High grade leiomyosarcoma (G2-3),\n",
      "             liposarcoma, if at least 30% of the tumour is dedifferentiated, pleomorphic\n",
      "             liposarcoma. A centralised diagnosis will be made to confirm that the patient can be\n",
      "             included in the study.\n",
      "\n",
      "          4. The tumour must be located in the retroperitoneum and it must be resectable and\n",
      "             without evidence of regional or distal spread after the appropriate staging process.\n",
      "\n",
      "          5. The location and size of the disease in the retroperitoneum must allow for compliance\n",
      "             with radiotherapy limitations in healthy tissue. This point must be confirmed by the\n",
      "             site's radiation oncologist.\n",
      "\n",
      "          6. Measurable disease according to RECIST V 1.1 criteria.\n",
      "\n",
      "          7. ECOG performance status 0-1.\n",
      "\n",
      "          8. Adequate haematological parameters (haemoglobin >10 g/dl, leukocytes ≥3,000/mm3,\n",
      "             neutrophils ≥1,500/mm3, platelets ≥100,000/mm3). Patients with plasma creatinine ≤1.6\n",
      "             mg/dl, transaminases ≤2.5 times the ULN, total bilirubin ≤ ULN, CPK ≤2.5 times ULN,\n",
      "             alkaline phosphatase ≤2.5 times ULN are acceptable. If the increase in alkaline\n",
      "             phosphatase is >2.5 times the ULN, the liver fraction of alkaline phosphatase and/or\n",
      "             GGT should be ≤ULN.\n",
      "\n",
      "          9. Fertile men or women must use an effective contraceptive method before starting the\n",
      "             study, during the study and for 6 months following the conclusion thereof. Women of\n",
      "             childbearing potential who participate in the study must undergo a pregnancy test\n",
      "             before starting the study.\n",
      "\n",
      "         10. Normal cardiac function with LVEF ≥50% by echocardiogram or MUGA.\n",
      "\n",
      "         11. HBV and HCV serology must be performed before including the patient in the study. If\n",
      "             HbsAg is positive, it is advisable to rule out a replicative phase (HbsAg*, DNA HBV+).\n",
      "             If positive, the patient's inclusion in the trial is not recommended, and it is at the\n",
      "             discretion of the investigator to administer preventive treatment with lamivudine. If\n",
      "             a potential patient is positive to anti-HCV antibodies, the presence of the virus will\n",
      "             be ruled out with a qualitative PCR, or the patient cannot be included in the study\n",
      "             (if the qualitative PCR test cannot be performed on the patient, they cannot be\n",
      "             included in the study).\n",
      "\n",
      "         12. Patient may have had one previous chemotherapy line.\n",
      "\n",
      "         13. The patient must have a central venous catheter for the administration of the\n",
      "             treatment.\n",
      "\n",
      "        Exclusion criteria\n",
      "\n",
      "          1. Unresectable tumours.\n",
      "\n",
      "          2. Location other than the retroperitoneum\n",
      "\n",
      "          3. Patients who have previously received systemic treatment (chemotherapy or\n",
      "             trabectedin).\n",
      "\n",
      "          4. Patients who underwent prior local treatment for retroperitoneal sarcoma: surgery or\n",
      "             radiotherapy in the tumour bed.\n",
      "\n",
      "          5. ECOG performance status ≥2.\n",
      "\n",
      "          6. Presence of metastasis or lymph node involvement of the tumour.\n",
      "\n",
      "          7. Previous history of another neoplastic disease with less than 5 years free of disease\n",
      "             except for basal cell carcinoma or properly treated in situ cervical cancer.\n",
      "\n",
      "          8. Significant cardiovascular disease (e.g. dyspnoea >2 NYHA).\n",
      "\n",
      "          9. A significant grade 3 or greater systemic disease on the NCI-CTCAE v4.03 scale, which\n",
      "             may limit the availability of the patient or which, in the opinion of the\n",
      "             investigator, may contribute to the toxicity caused by the study treatment.\n",
      "\n",
      "         10. Uncontrolled viral, mycotic or bacterial infections.\n",
      "\n",
      "         11. Known HIV-positive patients.\n",
      "\n",
      "         12. Pregnant or breast-feeding women.\n",
      "\n",
      "         13. Psychological, familial, social or geographical circumstances that limit the patient's\n",
      "             ability to comply with the protocol or informed consent form.\n",
      "\n",
      "         14. Patients who have participated in another clinical trial and/or have received another\n",
      "             investigational product in the 30 days prior to inclusion in the trial.\n",
      "      \n",
      "---- Sample 3 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          -  Pathology confirmed relapsed or refractory T-cell lymphoma (PTCL and stage >IBCTCL) at\n",
      "             treating institution\n",
      "\n",
      "          -  Relapse or progression after at least 1 systemic therapy\n",
      "\n",
      "          -  Age ≥18 years at the time of signing the informed consent form\n",
      "\n",
      "          -  Able to adhere to the study visit schedule and other protocol requirements\n",
      "\n",
      "          -  Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks\n",
      "             prior to treatment in this study. If there is progression of disease on that therapy\n",
      "             and all adverse effects have resolved to Grade 1 or baseline, in which case 2 weeks is\n",
      "             acceptable\n",
      "\n",
      "          -  Previous radiation, hormonal therapy, and surgery must have been discontinued at least\n",
      "             2 weeks prior to treatment in this study and adverse effects must have resolved. Lymph\n",
      "             node or other diagnostic biopsy within 2 weeks is not considered exclusionary\n",
      "\n",
      "          -  Systemic corticosteroids are permissible in the following circumstances:\n",
      "\n",
      "          -  Short course systemic corticosteroids for disease control, improvement of performance\n",
      "             status or non-cancer indication (≤ 7 days) must have been discontinued at least 7 days\n",
      "             prior to study treatment.\n",
      "\n",
      "          -  Ongoing administration of a stable dose of corticosteroid therapy (previously received\n",
      "             for ≥ 30 days) is permissible provided there is evidence of measurable disease and\n",
      "             there will be no increase in steroid dose during the clinical trial\n",
      "\n",
      "          -  ECOG performance status of ≤ 2 at study entry\n",
      "\n",
      "          -  Patients who have undergone autologous stem cell transplant > 6 months prior are\n",
      "             eligible\n",
      "\n",
      "          -  Patients who have undergone allogeneic stem cell transplant > 12 months, without\n",
      "             active graft-versus-host-disease, and not on immunosuppression for prevention of\n",
      "             graft-versus-host disease are eligible\n",
      "\n",
      "          -  Laboratory test results within these range:\n",
      "\n",
      "          -  Adequate hematologic function with screening laboratory assessment defined as:\n",
      "\n",
      "          -  Absolute neutrophil count >1,000 cells/mm3 (1.0 x 10^9/L)\n",
      "\n",
      "          -  Platelet count >75,000 cells/mm3 (75 x 10^9/L), if thrombocytopenia is due to bone\n",
      "             marrow involvement platelet count must be ≥ 50,000 cells/mm3\n",
      "\n",
      "          -  Hemoglobin >8.0 g/dL\n",
      "\n",
      "          -  Adequate hepatic and renal function with screening laboratory assessment defined as:\n",
      "\n",
      "          -  Serum aspartate transaminase (AST) or alanine transaminase (ALT)\n",
      "\n",
      "             ≤2.5 x upper limit of normal (ULN)\n",
      "\n",
      "          -  Creatinine <2.0 x ULN or Estimated Glomerular Filtration Rate GFR [Cockcroft-Gault] >\n",
      "             30 mL/min.\n",
      "\n",
      "          -  Bilirubin <1.5 x ULN [unless bilirubin rise is due to Gilbert's syndrome (as defined\n",
      "             by >80% unconjugated hyperbilirubinemia) or of nonhepatic origin]\n",
      "\n",
      "          -  Females of childbearing potential (FCBP)† must have a negative serum pregnancy test\n",
      "             and agree to use appropriate methods of birth control\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          -  Patients who have a standard curative option for their lymphoid malignancy at current\n",
      "             state of disease are excluded. For eligibility on this trial, allogeneic stem cell\n",
      "             transplantation is not considered a standard curative option\n",
      "\n",
      "          -  Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc.)\n",
      "             within 28 days of the first dose of study drug\n",
      "\n",
      "          -  Recent infection requiring intravenous anti-infective treatment that was completed ≤14\n",
      "             days before the first dose of study drug\n",
      "\n",
      "          -  Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia\n",
      "\n",
      "          -  Treatment with warfarin or other Vitamin K antagonists (eg, phenprocoumon)\n",
      "\n",
      "          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in\n",
      "             the opinion of the investigator, could compromise the subject's safety or put the\n",
      "             study outcomes at undue risk\n",
      "\n",
      "          -  Unwilling or unable to participate in all required study evaluations and procedures.\n",
      "\n",
      "          -  Unable to understand the purpose and risks of the study and to provide a signed and\n",
      "             dated informed consent form (ICF)\n",
      "\n",
      "          -  Currently active, clinically significant cardiovascular disease, such as uncontrolled\n",
      "             arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart\n",
      "             Association Functional Classification; or a history of myocardial infarction, unstable\n",
      "             angina, or acute coronary syndrome within 6 months prior to enrollment\n",
      "\n",
      "          -  Unable to swallow capsules, malabsorption syndrome, disease significantly affecting\n",
      "             gastrointestinal function, resection of the stomach or small bowel, symptomatic\n",
      "             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel\n",
      "             obstruction\n",
      "\n",
      "          -  Pregnant females (Lactating females must agree not to breast feed while taking\n",
      "             ibrutinib\n",
      "\n",
      "          -  Prior use of ibrutinib\n",
      "\n",
      "          -  Known seropositive and requiring anti-viral therapy for human immunodeficiency virus\n",
      "             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by PCR.\n",
      "\n",
      "          -  Active concurrent malignancy requiring active therapy\n",
      "\n",
      "          -  Known central nervous system or meningeal involvement (in the absence of symptoms\n",
      "             investigation into central nervous system involvement is not required)\n",
      "\n",
      "          -  Patients who require treatment with a strong cytochrome P450 (CYP) 3A inhibitor\n",
      "      \n",
      "---- Sample 4 ----\n",
      "\n",
      "        Inclusion Criteria:\n",
      "\n",
      "          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).\n",
      "\n",
      "          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved\n",
      "             stable disease or a partial response.\n",
      "\n",
      "          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR\n",
      "             mutant-positive for 3 months and achieved stable disease, partial response or\n",
      "             completely response.\n",
      "\n",
      "          4. Age 18 to 75 years old.\n",
      "\n",
      "          5. Patients must have measurable disease at baseline.\n",
      "\n",
      "          6. The amount of metastatic focus <5.\n",
      "\n",
      "          7. ECOG score 0-2\n",
      "\n",
      "          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.\n",
      "\n",
      "          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)\n",
      "\n",
      "         10. Patients must provide written informed consent to participate in the study.\n",
      "\n",
      "        Exclusion Criteria:\n",
      "\n",
      "          1. Patients who previously received radiotherapy to the primary site.\n",
      "\n",
      "          2. Patient can't tolerate radiotherapy or targeted therapy;\n",
      "\n",
      "          3. Pregnant or nursing women\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "module_dir = os.path.abspath('../../src')  # Gets the absolute path to the src directory\n",
    "sys.path.append(module_dir)\n",
    "from helper_functions import dataset_create_trials\n",
    "\n",
    "overwrite = False\n",
    "if trials_db_downloaded and not overwrite:\n",
    "    print(f'Trials database already downloaded and stored in {trials_path}')\n",
    "    df_trials = pd.read_csv(trials_path)\n",
    "else:\n",
    "    df_trials, trials_path = dataset_create_trials(status='recruiting')\n",
    "    trials_db_downloaded = True\n",
    "\n",
    "# print the ctriteria column value froom 4 random rows of the dataferam. use a for loop\n",
    "df_samples = df_trials.sample(4).reset_index(drop=True)\n",
    "for i in range(4):\n",
    "    print(f'---- Sample {i+1} ----')\n",
    "    print(df_samples.iloc[i]['criteria'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating Vectore Stores"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Vstore for policy database\n",
    "\n",
    "To create a vector store for the policy database, we will use perform local embedding via NomicEmbeddings.   \n",
    "Also, to treat each policy separately, we split the policies main document into per policy chunks.   \n",
    "Note that this is a problem specific strategy, and may not be appropriate for all RAG applications."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "12\n",
      "Vectore store loaded from existing chromadb\n",
      "12\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 5. **Regulatory Compliance**\\n   - **Ethics Approval**: All trials must have approval from the Institutional Review Board (IRB) or Ethics Committee.\\n   - **Data Privacy**: Patient data must be handled in compliance with data protection regulations (e.g., GDPR, HIPAA).\\n   - **Adverse Event Reporting**: Any adverse events must be reported according to institutional and regulatory guidelines.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 7. **Emergency Contact and Support**\\n   - **Emergency Contact**: Patients must provide emergency contact information.\\n   - **Support Systems**: Patients must have access to appropriate support systems (e.g., caregiver, family member) to assist them throughout the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 8. **Travel Restrictions**\\n   - **Travel Requirements**: Patients must be able to travel to the trial site regularly for check-ups and monitoring without significant hardship or risk.\\n   - **Travel History**: Patients who have traveled to areas with active outbreaks of infectious diseases within the past 3 months are not eligible.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 9. **Dietary and Lifestyle Restrictions**\\n   - **Dietary Compliance**: Patients must adhere to any dietary restrictions or requirements specified by the trial protocol.\\n   - **Lifestyle Modifications**: Patients must be willing to comply with lifestyle modifications required by the trial protocol, such as exercise regimens or smoking cessation.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 10. **Allergies and Sensitivities**\\n   - **Allergy Disclosure**: Patients must disclose any known allergies or sensitivities, particularly to medications, foods, or environmental factors.\\n   - **Medication Sensitivity**: Patients with known sensitivities to medications being tested in the trial are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 11. **Cognitive and Communication Abilities**\\n   - **Cognitive Assessment**: Patients must have the cognitive ability to understand and comply with the trial protocol and instructions.\\n   - **Communication Abilities**: Patients must be able to effectively communicate with the research team and understand instructions, either directly or with the assistance of a caregiver.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 12. **Employment and Daily Responsibilities**\\n   - **Employment Impact**: Patients must disclose if participation in the trial could impact their employment or daily responsibilities significantly.\\n   - **Availability**: Patients must be available for all scheduled trial visits and assessments as required by the protocol, with minimal risk of missing appointments.', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import WebBaseLoader\n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_nomic.embeddings import NomicEmbeddings\n",
    "from langchain_community.document_loaders import UnstructuredMarkdownLoader\n",
    "from langchain_core.documents import Document\n",
    "import chromadb\n",
    "\n",
    "# vstore_delete = False\n",
    "vstore_load = True\n",
    "markdown_path = \"../../source_data/instut_trials_policy.md\"\n",
    "\n",
    "with open(markdown_path, \"r\") as f:\n",
    "    policy_text = f.read()\n",
    "\n",
    "\n",
    "doc_splits = [\n",
    "    Document(page_content= txt, metadata={\"source\": markdown_path}) for txt in re.split(r\"(?=\\n###)\", policy_text)\n",
    "    ]\n",
    "\n",
    "# the title of markdown is not required in the split\n",
    "doc_splits = doc_splits[1:]    \n",
    "\n",
    "print(len(doc_splits))\n",
    "doc_splits\n",
    "\n",
    "persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "if vstore_load == False:\n",
    "    vectorstore.delete_collection()\n",
    "\n",
    "\n",
    "# if chromadb_path exists\n",
    "if os.path.exists(chromadb_path) and vstore_load:\n",
    "    vectorstore = Chroma(\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store loaded from existing chromadb')\n",
    "    # vectorstore._collection.count()\n",
    "else:\n",
    "    vectorstore = Chroma.from_documents(\n",
    "        documents=doc_splits,\n",
    "        client=persistent_client,\n",
    "        collection_name=policy_collection,\n",
    "        # persist_directory=chromadb_path,\n",
    "        embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    print('Vectore store created and stored in persistent chromadb client')\n",
    "print(vectorstore._collection.count())\n",
    "doc_splits\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Vstore for trials"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For simplicy, we just work on 3 main categories of cancer, lukemia, and mental health problems.   \n",
    "This selection gives us a managable set of trials as a demo application.   \n",
    "However, for a more proper application, categories can be extended with the help of domain specialists.\n",
    "\n",
    "The vectore store is created using chromadb and as a persistent client."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}\n",
      "Loading the vectorstore from persistent client\n",
      "18\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Provide written informed consent to participate on the study\\r\\n\\r\\n          -  Patients must have a pathologically confirmed diagnosis either at MSKCC or at the\\r\\n             participating site of stage I-III malignant pleural mesothelioma\\r\\n\\r\\n          -  Epithelioid or biphasic histology subtype (Note: patients with biphasic histology can\\r\\n             have < 10% sarcomatoid)\\r\\n\\r\\n          -  No evidence of metastatic disease.\\r\\n\\r\\n          -  Patient age ≥ 18 years but ≤ 80 years at the time of consent.\\r\\n\\r\\n          -  Karnofsky performance status ≥ 80%\\r\\n\\r\\n          -  Pulmonary Function Tests:\\r\\n\\r\\n               1. For all patients: DLCO > 40% predicted (corrected for Hgb)\\r\\n\\r\\n               2. For patients enrolled post-P/D, only: FEV1 >/= 35% (corrected for Hgb) (Note:\\r\\n                  patients enrolled prior to P/D will have PFTs repeated pre-IMRT. If this criteria\\r\\n                  is not met, they will be removed from study)\\r\\n\\r\\n          -  In cases of concern about decreased renal function and potential high radiation dose\\r\\n             to the kidneys, an optional nuclear medicine kidney function scan may be performed\\r\\n             prior to radiation therapy to determine the functional contribution of each kidney.\\r\\n\\r\\n          -  Patient enrolled prior to chemotherapy must have adequate organ function as indicated\\r\\n             by the following laboratory values:\\r\\n\\r\\n               1. Absolute neutrophil count ≥1.5 K/mcL\\r\\n\\r\\n               2. Platelets ≥100 K/mcL\\r\\n\\r\\n               3. Serum total bilirubin ≤ 1.5 X ULN\\r\\n\\r\\n               4. AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN Note: patients enrolled after chemotherapy\\r\\n                  do not have to meet the above criteria\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  > 10% Sarcomatoid or desmoplastic histology\\r\\n\\r\\n          -  Continuous oxygen use\\r\\n\\r\\n          -  Prior nephrectomy on the contralateral side of MPM\\r\\n\\r\\n          -  Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of\\r\\n             P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)\\r\\n\\r\\n          -  Prior thoracic radiation therapy preventing hemithoracic pleural IMRT\\r\\n\\r\\n          -  Bulky disease in the fissure preventing lung-sparing pleural IMRT\\r\\n\\r\\n          -  Patients undergoing extrapleural pneumonectomy\\r\\n\\r\\n          -  Patients with an active infection that require systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a concurrent active malignancy (except squamous or basal cell carcinoma\\r\\n             of the skin)\\r\\n\\r\\n          -  Patients with serious unstable medical illness\\r\\n\\r\\n          -  Presence of third space fluid that cannot be controlled by drainage\\r\\n\\r\\n          -  For patients who develop or have baseline clinically significant pleural effusions\\r\\n             before or during initiation of pemetrexed therapy; consideration should be given to\\r\\n             drain the effusion prior to chemotherapy administration\\r\\n\\r\\n          -  No acute congestive heart failure\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Men or women not using effective contraception\\r\\n\\r\\n        Reproductive risks Patients should not become pregnant or father a baby while on this study\\r\\n        because the drugs in this study can affect an unborn baby. Women should not breast-feed a\\r\\n        baby while on this study. Women of childbearing age will be counseled to use birth control\\r\\n        while on this study.\\r\\n      ', metadata={'nctid': 'NCT00715611', 'status': 'recruiting', 'diseases': \"['mesothelioma']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed and cisplatin or carboplatin']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III\\r\\n             according to the International Staging System ISS (see appendix A), i.e. at least one\\r\\n             of the CRAB criteria should be present;\\r\\n\\r\\n          -  Measurable disease as defined by the presence of M-protein in serum or urine (serum\\r\\n             M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain\\r\\n             ratio;\\r\\n\\r\\n          -  Age 18-65 years inclusive;\\r\\n\\r\\n          -  WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by\\r\\n             comorbid conditions);\\r\\n\\r\\n          -  Negative pregnancy test at inclusion if applicable;\\r\\n\\r\\n          -  Written informed consent.\\r\\n\\r\\n        Inclusion for randomisation 1:\\r\\n\\r\\n          -  WHO performance 0-2;\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to\\r\\n             national guidelines).\\r\\n\\r\\n        Inclusion for randomisation 2:\\r\\n\\r\\n          -  Bilirubin and transaminases < 2.5 times the upper limit of normal values;\\r\\n\\r\\n          -  ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;\\r\\n\\r\\n          -  Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention\\r\\n             Risk Management Plan.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Known intolerance of Boron;\\r\\n\\r\\n          -  Systemic AL amyloidosis;\\r\\n\\r\\n          -  Primary Plasmacell Leukemia;\\r\\n\\r\\n          -  Non-secretory MM;\\r\\n\\r\\n          -  Previous chemotherapy or radiotherapy except local radiotherapy in case of local\\r\\n             myeloma progression or corticosteroids maximum 5 days for symptom control;\\r\\n\\r\\n          -  Severe cardiac dysfunction (NYHA classification II-IV);\\r\\n\\r\\n          -  Significant hepatic dysfunction, unless related to myeloma;\\r\\n\\r\\n          -  Patients with GFR <15 ml/min,\\r\\n\\r\\n          -  Patients known to be HIV-positive;\\r\\n\\r\\n          -  Patients with active, uncontrolled infections;\\r\\n\\r\\n          -  Patients with neuropathy, CTC grade 2 or higher;\\r\\n\\r\\n          -  Patients with a history of active malignancy during the past 5 years with the\\r\\n             exception of basal carcinoma of the skin or stage 0 cervical carcinoma;\\r\\n\\r\\n          -  Patients who are not willing or capable to use adequate contraception during the\\r\\n             therapy (all men, all pre-menopausal women);\\r\\n\\r\\n          -  Lactating women.\\r\\n\\r\\n        Exclusion for randomisation 1:\\r\\n\\r\\n          -  Severe pulmonary, neurologic, or psychiatric disease;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;\\r\\n\\r\\n          -  Allogeneic Stem Cell Transplantation (Allo SCT) planned;\\r\\n\\r\\n          -  Progressive disease.'\\r\\n\\r\\n        Exclusion for randomisation 2:\\r\\n\\r\\n          -  Progressive disease;\\r\\n\\r\\n          -  Neuropathy, except CTCAE grade 1;\\r\\n\\r\\n          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.\\r\\n      \", metadata={'nctid': 'NCT01208766', 'status': 'recruiting', 'diseases': \"['multiple myeloma']\", 'disease_category': 'cancer', 'drugs': \"['bortezomib, melphalan, prednisone (vmp)', '1 or 2 cycle(s) hdm (high dose melphalan)', '2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been\\r\\n             previously treated with docetaxel-based therapy and has progressed during treatment of\\r\\n             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)\\r\\n\\r\\n          -  Two rising PSA levels greater than or equal to (>/=) 2 ng/mL measured >/= 1 week apart\\r\\n             or radiographic evidence of disease progression in soft tissue or bone\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening\\r\\n\\r\\n          -  Adequate hematologic and organ function\\r\\n\\r\\n          -  Documented willingness to use an effective means of contraception\\r\\n\\r\\n          -  Safety cohort only: agreement to use CGM for first cycle of treatment\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:\\r\\n             patients who are receiving any pharmacologic treatment for diabetes are not eligible\\r\\n\\r\\n          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection\\r\\n             fraction < 50% or ventricular arrhythmia requiring medication\\r\\n\\r\\n          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of\\r\\n             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident\\r\\n             within 6 months prior to Day 1\\r\\n\\r\\n          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory\\r\\n             drugs or active inflammatory disease which requires immunosuppressive therapy\\r\\n\\r\\n          -  Clinically significant history of liver disease\\r\\n\\r\\n          -  History of adrenal insufficiency or hyperaldosteronism\\r\\n\\r\\n          -  Phase II only: Previous therapy for prostate cancer with 17\\r\\n             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone\\r\\n\\r\\n          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B\\r\\n             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors\\r\\n\\r\\n          -  Need for chronic corticosteroid therapy of >/= 20 mg of prednisone per day or an\\r\\n             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant\\r\\n      ', metadata={'nctid': 'NCT01485861', 'status': 'recruiting', 'diseases': \"['prostate cancer']\", 'disease_category': 'cancer', 'drugs': \"['abiraterone', 'apitolisib', 'ipatasertib', 'placebo', 'prednisone', 'prednisolone']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients have provided a signed Informed Consent Form\\r\\n\\r\\n          -  ECOG performance status of 0-1\\r\\n\\r\\n          -  BMI ≥ 18.5\\r\\n\\r\\n          -  Age: 18-65 years old\\r\\n\\r\\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\\r\\n\\r\\n          -  No prior palliative chemotherapy\\r\\n\\r\\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria\\r\\n\\r\\n          -  Life expectancy ≥ 3 months\\r\\n\\r\\n          -  Patient has adequate bone marrow and organ function\\r\\n\\r\\n               -  Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L\\r\\n\\r\\n               -  Platelets ≥ 90 x 109/L\\r\\n\\r\\n               -  Hemoglobin ≥ 90 g/L\\r\\n\\r\\n          -  Patient has adequate liver function\\r\\n\\r\\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\\r\\n                  liver metastasis)\\r\\n\\r\\n               -  Serum bilirubin ≤ 1.2 x ULN\\r\\n\\r\\n          -  Creatinine ≤ 1.25 times ULN\\r\\n\\r\\n          -  Good compliance\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Brain metastasis or only with bone metastasis.\\r\\n\\r\\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\\r\\n             transfusions.\\r\\n\\r\\n          -  Refuse to take appropriate contraceptive measures (including male patients).\\r\\n\\r\\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\\r\\n\\r\\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\\r\\n             cardiac, liver, renal diseases.\\r\\n\\r\\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\\r\\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\\r\\n             situ).\\r\\n\\r\\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\\r\\n\\r\\n          -  Patient is concurrently using other antineoplastic agent\\r\\n\\r\\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\\r\\n\\r\\n          -  Known HIV-positivity.\\r\\n\\r\\n          -  No history of chronic diarrhea, nausea or vomit.\\r\\n\\r\\n          -  No ≥ grade 2 sensory peripheral neuropathy.\\r\\n\\r\\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\\r\\n             congestive heart failure, and unstable angina.\\r\\n\\r\\n          -  Infectious disease or inflammation with body temperature ≥ 38 ℃.\\r\\n      ', metadata={'nctid': 'NCT02028806', 'status': 'recruiting', 'diseases': \"['metastatic pancreatic cancer']\", 'disease_category': 'cancer', 'drugs': \"['mfolfirinox']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n        Suicidal Ideation group:\\r\\n\\r\\n          1. Any person admitted to the emergency room department after a suicide attempt , defined\\r\\n             as requiring medical intervention - not just a psychiatrist ( surgical or\\r\\n             pharmacological treatment but also the need for observation ) .\\r\\n\\r\\n          2. The need for medical intervention will be defined by the ER ED physician\\r\\n\\r\\n          3. Ages 18-65\\r\\n\\r\\n        For the depression group:\\r\\n\\r\\n          1. Diagnosed with major depression according to DSM VI.\\r\\n\\r\\n          2. Ongoing depression (according to DSM criteria) despite treatment with at least two\\r\\n             antidepressants in adequate dosages and for longer than three weeks.\\r\\n\\r\\n          3. Ages 18-65\\r\\n\\r\\n        For the romantic relationship breakup:\\r\\n\\r\\n        1. Participants that have experienced a meaningful romantic relationship break-up within\\r\\n        the past 12 months\\r\\n\\r\\n        -\\r\\n\\r\\n        Exclusion Criteria for all groups:\\r\\n\\r\\n          1. Psychotic state instate in the examination\\r\\n\\r\\n          2. Diagnosis of schizophrenia / schizoaffective disorder\\r\\n\\r\\n          3. Drug or alcohol abuse as is revealed in by blood/urine tests\\r\\n\\r\\n          4. Patient in which, according to the examiner, there is primary or secondary gain.\\r\\n\\r\\n          5. Patient , which, at the time of his admission , is without any pharmacological\\r\\n             treatment.\\r\\n      ', metadata={'nctid': 'NCT02037503', 'status': 'recruiting', 'diseases': \"['suicidal ideation', 'major depressive disorder', 'healthy participants']\", 'disease_category': 'mental_health', 'drugs': \"['ketamine', 'saline']\"}),\n",
       " Document(page_content=\"\\n        Key Inclusion Criteria:\\r\\n\\r\\n          -  Subject must be ≥18 years of age.\\r\\n\\r\\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\\r\\n             based on local or central evaluation.\\r\\n\\r\\n          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\\r\\n             and urine sampling during the study.\\r\\n\\r\\n          -  Subjects must have ECOG PS of 0 to 2.\\r\\n\\r\\n          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\\r\\n\\r\\n          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\\r\\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\\r\\n             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\\r\\n             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\\r\\n             disease\\r\\n\\r\\n          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\\r\\n             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\\r\\n             rate (GFR)\\r\\n\\r\\n          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\\r\\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\\r\\n\\r\\n          -  Female subjects with reproductive potential must have a negative serum pregnancy test\\r\\n             within 7 days prior to the start of therapy and on the first day of study drug\\r\\n             administration.\\r\\n\\r\\n        Key Exclusion Criteria:\\r\\n\\r\\n          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\\r\\n             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\\r\\n             time of screening, or with clinically significant graft-versus-host disease (GVHD).\\r\\n             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\\r\\n             GVHD is permitted.)\\r\\n\\r\\n          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\\r\\n             their first day of study drug administration. (Hydroxyurea is allowed prior to\\r\\n             enrollment and after the start of AG-120).\\r\\n\\r\\n          -  Subjects who received an investigational agent <14 days prior to their first day of\\r\\n             study drug administration.\\r\\n\\r\\n          -  Subjects who are pregnant or breastfeeding.\\r\\n\\r\\n          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\\r\\n             screening visits or on their first day of study drug administration (at the discretion\\r\\n             of the Investigator, subjects with tumor fever may be enrolled).\\r\\n\\r\\n          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\\r\\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\\r\\n             within approximately 28 days of C1D1.\\r\\n\\r\\n          -  Subjects with a history of myocardial infarction within the last 6 months of\\r\\n             screening.\\r\\n\\r\\n          -  Subjects with a known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\\r\\n\\r\\n          -  Subjects with known unstable or uncontrolled angina pectoris.\\r\\n\\r\\n          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\\r\\n             increase the risk of QT prolongation or arrhythmic events.\\r\\n\\r\\n          -  Patients taking medications that are known to prolong the QT interval\\r\\n\\r\\n          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\\r\\n             hepatitis B or C.\\r\\n\\r\\n          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\\r\\n             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\\r\\n             there is a clinical suspicion of CNS involvement by leukemia during screening.\\r\\n\\r\\n          -  Subjects with immediately life-threatening, severe complications of leukemia such as\\r\\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\\r\\n             intravascular coagulation.\\r\\n      \", metadata={'nctid': 'NCT02074839', 'status': 'recruiting', 'diseases': \"['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\", 'disease_category': 'leukemia', 'drugs': \"['ag-120']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Participant has the ability and the willingness to sign the informed consent document\\r\\n             (for adults only, for participants with mild cognitive abilities may use a legally\\r\\n             authorized representative)\\r\\n\\r\\n          -  Documented (signed) informed consent; the patient, family member and transplant staff\\r\\n             physician (physician, nurse, and social worker) meet at least once prior to starting\\r\\n             the transplant procedure; during this meeting all pertinent information with respect\\r\\n             to risks and benefits to donor and recipient will be presented; alternative treatment\\r\\n             modalities will be discussed; the risks are explained in detail in the enclosed\\r\\n             consent forms\\r\\n\\r\\n          -  Karnofsky performance status >= 70% =< 2\\r\\n\\r\\n          -  Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first\\r\\n             remission or second remission i.e. after failing induction therapy, or in relapse or\\r\\n             beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)\\r\\n\\r\\n          -  All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR)\\r\\n             identical siblings who is willing to donate bone marrow or primed blood stem cells or\\r\\n             a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ\\r\\n             and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO\\r\\n             blood group combinations of the donor/recipient are acceptable\\r\\n\\r\\n          -  The time from the end last induction, re-induction, or consolidation regimen should be\\r\\n             greater than or equal to 14 days from planned start of study treatment; Note:\\r\\n             Chemotherapy given within 14 days of planned study enrollment for the purpose of\\r\\n             controlling counts is permitted\\r\\n\\r\\n          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert\\'s disease\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) =< 5 x ULN\\r\\n\\r\\n          -  Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum\\r\\n             creatinine =< 1.3 mg/dL\\r\\n\\r\\n          -  Women of child bearing potential only: Negative urine or serum pregnancy test\\r\\n\\r\\n          -  Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon\\r\\n             monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted\\r\\n             normal value\\r\\n\\r\\n          -  Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >=\\r\\n             50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall\\r\\n             motion is \"abnormal\" or \"altered\")\\r\\n\\r\\n          -  Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm\\r\\n\\r\\n          -  Agreement of men AND women-of-child-bearing-potential to use adequate contraception\\r\\n             (hormonal or barrier method of birth control or abstinence) prior to study entry and\\r\\n             for six months following duration of study participation; should a woman become\\r\\n             pregnant or suspect that she is pregnant while participating on the trial, she should\\r\\n             inform her treating physician immediately\\r\\n\\r\\n          -  DONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current\\r\\n             City of Hope standard operating procedure (SOP)\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Prior autologous or allogeneic hematopoietic stem cell\\r\\n\\r\\n          -  Prior radiation therapy that would exclude the use of TMLI\\r\\n\\r\\n          -  Plans during the trial to receive any other (non-trial) investigational agents, or\\r\\n             concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white\\r\\n             blood count control is permitted)\\r\\n\\r\\n          -  Uncontrolled illness including ongoing or active infection\\r\\n\\r\\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\\r\\n             composition to etoposide\\r\\n\\r\\n          -  Patients with other active malignancies are ineligible for this study, other than\\r\\n             localized malignancies\\r\\n\\r\\n          -  Patients with psychological or medical condition that patient\\'s physician deems\\r\\n             unacceptable to proceed to allogeneic hematopoietic stem cell transplantation\\r\\n\\r\\n          -  Women who are planning to become pregnant or breast feed during the trial\\r\\n\\r\\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\\r\\n             safety monitoring requirements of the study\\r\\n      ', metadata={'nctid': 'NCT02094794', 'status': 'recruiting', 'diseases': \"['adult acute myeloid leukemia with 11q23 (mll) abnormalities', 'adult acute myeloid leukemia with del(5q)', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia']\", 'disease_category': 'leukemia', 'drugs': \"['etoposide', 'cyclophosphamide']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically proven non-small-cell lung cancer (core biopsy required).\\r\\n\\r\\n               -  Squamous or non-squamous histology\\r\\n\\r\\n               -  Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at\\r\\n                  SKCCC or MSKCC\\r\\n\\r\\n               -  Either a formalin fixed paraffin block or a minimum of fifteen 5-micron tissue\\r\\n                  sections (slides) of tumor biopsy sample must be available for biomarker\\r\\n                  evaluation (study pathologist must review for adequacy of sampling). This can be\\r\\n                  obtained from archived tissues, or from a new biopsy if needed.\\r\\n\\r\\n          -  Stage - High risk NSCLC with resection option for potential cure, as assessed by a\\r\\n             faculty surgeon at SKCCC or MSKCC. This may include clinical stage IB (≥4cm), II and\\r\\n             IIIA(see Appendix A). Subjects with N3 nodal involvement are not included.\\r\\n\\r\\n        ECOG performance status 0-1\\r\\n\\r\\n        -Adequate organ function as follows:\\r\\n\\r\\n          -  Leukocytes ≥ 2,000/mm3\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) ≥ 1000/mm3\\r\\n\\r\\n          -  Platelet count ≥ 100,000/mm3\\r\\n\\r\\n          -  Hemoglobin ≥ 9 g/dL\\r\\n\\r\\n          -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥40 mL/min (if using the\\r\\n             Cockcroft-Gault formula below):\\r\\n\\r\\n        Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL\\r\\n\\r\\n        Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL\\r\\n\\r\\n          -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total\\r\\n             bilirubin < 3.0 mg/dL)\\r\\n\\r\\n          -  AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 3 times the upper limit of normal\\r\\n\\r\\n          -  Subjects must have adequate lung function to permit surgical resection determined by\\r\\n             pre-enrollment pulmonary function tests to include DLCO\\r\\n\\r\\n               -  The effects of nivolumab on the developing human fetus are unknown. For this\\r\\n                  reason, women of child-bearing potential (WOCBP) and men must agree to use\\r\\n                  adequate contraception (hormonal or barrier method of birth control; abstinence)\\r\\n                  prior to study entry and for the duration of study participation and for up to 23\\r\\n                  weeks after the last dose of nivolumab. Should a woman become pregnant or suspect\\r\\n                  she is pregnant while she or her partner is participating in this study, she\\r\\n                  should inform her treating physician immediately. Sexually active fertile men\\r\\n                  must use effective barrier birth control if their partners are WOCBP for up to 31\\r\\n                  weeks after the last dose of nivolumab. WOCBP must have a negative serum or urine\\r\\n                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within\\r\\n                  two weeks of registration. Women must not be breastfeeding.\\r\\n\\r\\n               -  Patient understands the study regimen, its requirements, risks and discomforts\\r\\n                  and is able and willing to sign the informed consent form. Voluntary signed and\\r\\n                  dated IRB/IEC approved written informed consent form in accordance with\\r\\n                  regulatory and institutional guidelines must be obtained before the performance\\r\\n                  of any protocol related procedures that are not part of normal patient care.\\r\\n                  Subjects must be competent to report AEs, understand the drug dosing schedule and\\r\\n                  use of medications to control AEs.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Subjects are excluded if they have an active, known or suspected autoimmune disease.\\r\\n             Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus,\\r\\n             residual hypothyroidism due to autoimmune condition only requiring hormone\\r\\n             replacement, psoriasis not requiring systemic treatment, or conditions not expected to\\r\\n             recur in the absence of an external trigger.\\r\\n\\r\\n          -  Subjects are excluded if they have a condition requiring systemic treatment with\\r\\n             either corticosteroids (> 10 mg daily prednisone equivalents) or other\\r\\n             immunosuppressive medications within 14 days of study drug administration. Inhaled or\\r\\n             topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents\\r\\n             are permitted in the absence of active autoimmune disease. As there is potential for\\r\\n             hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a\\r\\n             predisposition to hepatoxicity should be used with caution in patients treated with\\r\\n             nivolumab-containing regimen.\\r\\n\\r\\n          -  Administration of chemotherapy or any other cancer therapy in the pre-operative\\r\\n             period.\\r\\n\\r\\n          -  Subjects with active concurrent malignancies are excluded i.e. cancers other than\\r\\n             NSCLC (except non melanoma skin cancers, in situ bladder, gastric, breast, colon or\\r\\n             cervical cancers/dysplasia).\\r\\n\\r\\n          -  Subjects with brain metastasis are excluded from this study, and all patients should\\r\\n             have brain imaging (either MRI brain or CT brain with contrast) prior to enrollment.\\r\\n\\r\\n          -  Subjects with a history of symptomatic interstitial lung disease.\\r\\n\\r\\n          -  Active systemic infection requiring therapy, positive tests for Hepatitis B surface\\r\\n             antigen or Hepatitis C ribonucleic acid (RNA).\\r\\n\\r\\n          -  Known positive history or positive test for Human Immunodeficiency Virus or Acquired\\r\\n             ImmunoDeficiency Syndrome (AIDS).\\r\\n\\r\\n          -  History of allergy to study drug components.\\r\\n\\r\\n          -  Women who are pregnant or nursing.\\r\\n\\r\\n          -  Men with female partners (WOCBP) that are not willing to use contraception.\\r\\n\\r\\n          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or\\r\\n             any other antibody targeting T cell co-regulatory pathways).\\r\\n\\r\\n          -  Underlying medical conditions that, in the Investigator's opinion, will make the\\r\\n             administration of study drug hazardous or obscure the interpretation of toxicity or\\r\\n             adverse events.\\r\\n\\r\\n          -  Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for\\r\\n             treatment of either a psychiatric or physical (e.g. infectious disease) illness.\\r\\n      \", metadata={'nctid': 'NCT02259621', 'status': 'recruiting', 'diseases': \"['non-small cell lung cancer']\", 'disease_category': 'cancer', 'drugs': \"['nivolumab']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Histologically confirmed locally advanced gastric (primary endpoint includes proximal\\r\\n             and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral)\\r\\n             adenocarcinomas are eligible for enrolment but will not be included in the primary\\r\\n             analysis\\r\\n\\r\\n          -  Locally advanced disease as determined by endoscopic ultrasound (EUS) stage > primary\\r\\n             tumor (T) 3 and/or any T, lymph nodes (N)+ disease without metastatic disease (Mx)\\r\\n\\r\\n          -  All patients must have diagnostic laparoscopy with diagnostic washings for cytology;\\r\\n             both cytology positive and negative patients are eligible for enrolment, but only\\r\\n             cytology negative patients will be included in the primary analyses; gross peritoneal\\r\\n             disease is not eligible\\r\\n\\r\\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1\\r\\n\\r\\n          -  Eligible for surgery with curative intent\\r\\n\\r\\n          -  Absolute neutrophil count (ANC) >= 1250/ul\\r\\n\\r\\n          -  Hemoglobin >= 9 g/dL\\r\\n\\r\\n          -  Platelets >= 100,000/ul\\r\\n\\r\\n          -  Total bilirubin < 1.5 x upper limit of normal\\r\\n\\r\\n          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate\\r\\n             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver\\r\\n             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver\\r\\n             metastases\\r\\n\\r\\n          -  Creatinine =< 1.5 x upper limit of normal\\r\\n\\r\\n          -  Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor\\r\\n             (RECIST) 1.1 will be allowed\\r\\n\\r\\n          -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and for\\r\\n             the duration of study participation, up until 30 days after final study treatment;\\r\\n             should a woman become pregnant or suspect that she is pregnant while participating in\\r\\n             this study, she should inform her treating physician immediately\\r\\n\\r\\n          -  Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3,\\r\\n             subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative\\r\\n             drugs whenever possible, given the potential for drug-drug interactions with\\r\\n             irinotecan\\r\\n\\r\\n          -  Signed informed consent\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Previous or concurrent malignancy, except for adequately treated basal cell or\\r\\n             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the\\r\\n             patient has been previously treated and the lifetime recurrence risk is less than 30%\\r\\n\\r\\n          -  Inflammatory bowel disease that is uncontrolled or on active treatment (Crohn's\\r\\n             disease, ulcerative colitis)\\r\\n\\r\\n          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology\\r\\n             Criteria for Adverse Events (NCI-CTCAE, version [v] 4.0)\\r\\n\\r\\n          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0\\r\\n\\r\\n          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the\\r\\n             treating physician, substantially increase the risk for complications related to\\r\\n             treatment\\r\\n\\r\\n          -  Active uncontrolled bleeding\\r\\n\\r\\n          -  Pregnancy or breastfeeding\\r\\n\\r\\n          -  Major surgery within 4 weeks\\r\\n\\r\\n          -  Patients with any polymorphism in UGT1A1 other than *1 or *28 (e.g, *6) will be\\r\\n             allowed and treated as in the *28/*28 dosing group\\r\\n      \", metadata={'nctid': 'NCT02366819', 'status': 'recruiting', 'diseases': \"['esophageal adenocarcinoma', 'gastric adenocarcinoma', 'stage iib gastric cancer', 'stage iiia esophageal adenocarcinoma', 'stage iiia gastric cancer', 'stage iiib esophageal adenocarcinoma', 'stage iiib gastric cancer', 'stage iiic esophageal adenocarcinoma', 'stage iiic gastric cancer']\", 'disease_category': 'cancer', 'drugs': \"['oxaliplatin', 'leucovorin calcium', 'irinotecan hydrochloride', 'fluorouracil']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma\\r\\n             (Islet cell neoplasms or neuroendocrine carcinomas are excluded)\\r\\n\\r\\n          2. ≥ 18 years of age at the time of signing the informed consent document\\r\\n\\r\\n          3. ECOG 0-1\\r\\n\\r\\n          4. At least one measurable lesion according to recist v1.1\\r\\n\\r\\n          5. No prior palliative chemotherapy for the treatment of metastatic pancreatic cancer\\r\\n             (Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in\\r\\n             the adjuvant setting is allowed if the treatment had been received at least 6 months\\r\\n             before enroll).\\r\\n\\r\\n          6. Adequate BM function: ANC ≥1.5 × 109/L; Platelet count ≥100,000/mm2 (100 × 109/L); Hb\\r\\n             (Hb) ≥9 g/dL.\\r\\n\\r\\n          7. Adequate liver and renal function (obtained ≤14 days prior to enroll): AST (SGOT), ALT\\r\\n             (SGPT) ≤2.5 × upper limit of normal range (ULN), unless liver metastases are clearly\\r\\n             present, then ≤5 × ULN is allowed; Total bilirubin 1.5 ≤ ULN; Serum creatinine within\\r\\n             normal limits or calculated clearance ≥ 60 mL/min/1.73 m2\\r\\n\\r\\n          8. Albumin level ≥ 3 g/dl\\r\\n\\r\\n          9. Subjects should be asymptomatic for jaundice prior to Cycle 1 Day 1\\r\\n\\r\\n         10. Subject with signed the Informed Consent Form (ICF) prior to participation in any\\r\\n             study-related activities.\\r\\n\\r\\n         11. Female of childbearing potential (FCBP) (defined as a sexually mature woman who (1)\\r\\n             has not undergone hysterectomy [the surgical removal of the uterus] or bilateral\\r\\n             oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally\\r\\n             postmenopausal for at least 24 consecutive months [ie, has had menses at any time\\r\\n             during the preceding 24 consecutive months]) must:\\r\\n\\r\\n               -  Either commit to true abstinence or agree to the use of 2 physician-approved\\r\\n                  contraceptive methods (oral, injectable, or implantable hormonal contraceptive;\\r\\n                  tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or\\r\\n                  vasectomized partner) while on IP; and for 3 months following the last dose of\\r\\n                  IP; and\\r\\n\\r\\n               -  Has a negative serum pregnancy test (β-hCG) result at screening\\r\\n\\r\\n         12. Male subjects must practice true abstinence or agree to use a condom during sexual\\r\\n             contact with a pregnant female or a female of childbearing potential while\\r\\n             participating in the study, during dose interruptions, and for 6 months following IP\\r\\n             discontinuation, even if he has undergone a successful vasectomy\\r\\n\\r\\n         13. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Subject has known symptomatic brain metastases.\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Breast-feeding or pregnant female\\r\\n\\r\\n          4. Patients with plastic biliary stent (Metal biliary stents are allowed.)\\r\\n\\r\\n          5. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\\r\\n             systemic therapy.\\r\\n\\r\\n          6. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          7. Subject has undergone major surgery within 4 weeks prior to Cycle 1 Day 1 of treatment\\r\\n             in this study.\\r\\n\\r\\n          8. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n\\r\\n          9. Subject has a history of allergy or hypersensitivity to any of the study drugs\\r\\n\\r\\n         10. Subjects with history of connective tissue disorders (eg, lupus, scleroderma,\\r\\n             arteritis nodosa).\\r\\n\\r\\n         11. Subjects with a history of interstitial lung disease\\r\\n\\r\\n         12. Any other malignancy within 5 years prior to enrollment, with the exception of\\r\\n             adequately treated in-situ carcinoma of the prostate (Gleason score ≤ 7), cervix,\\r\\n             uteri, or nonmelanomatous skin cancer (all treatment of which should have been\\r\\n             completed 6 months prior to enrollment).\\r\\n\\r\\n         13. Patients has > Grade 1 pre-existing peripheral neuropathy (per CTCAE)\\r\\n\\r\\n         14. Subject has serious medical risk factors involving any of the major organ systems, or\\r\\n             serious psychiatric disorders, which could compromise the subject's safety or the\\r\\n             study data integrity.\\r\\n\\r\\n         15. Subject is enrolled in any other clinical protocol or investigational trial with an\\r\\n             interventional agent or assessments that may interfere with study procedures.\\r\\n\\r\\n         16. Subject is unwilling or unable to comply with study procedures\\r\\n\\r\\n         17. Any significant medical condition, laboratory abnormality, or psychiatric illness that\\r\\n             would prevent the subject from participating in the study.\\r\\n      \", metadata={'nctid': 'NCT02426281', 'status': 'recruiting', 'diseases': \"['pancreatic ductal adenocarcinoma']\", 'disease_category': 'cancer', 'drugs': \"['nab-paclitaxel', 'gemcitabine']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Subject is at least 20 years of age.\\r\\n\\r\\n          2. Written and voluntary informed consent understood, signed and dated.\\r\\n\\r\\n          3. They must have refractory or progressive colorectal cancer for which there is no\\r\\n             further curative therapy available.\\r\\n\\r\\n          4. Subject able to adhere to the study visit schedule and other protocol requirements.\\r\\n\\r\\n          5. ECOG 0-2\\r\\n\\r\\n          6. At least one measurable lesion that can be accurately assessed by imaging or physical\\r\\n             examination at baseline and following up visits.\\r\\n\\r\\n          7. Must have a life expectancy of 3 months or more\\r\\n\\r\\n          8. Demonstrate adequate organ function\\r\\n\\r\\n          9. Negative urine or serum pregnancy test within 28 days of study treatment\\r\\n\\r\\n         10. Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy\\r\\n             of the tissue sample quality for assessment of biomarker status.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. ECOG ≥ 3\\r\\n\\r\\n          2. History of malignancy in the last 5 years.\\r\\n\\r\\n          3. Subject has known historical or active infection with HIV, hepatitis B, or hepatitis\\r\\n             C.\\r\\n\\r\\n          4. Breast-feeding or pregnant female\\r\\n\\r\\n          5. Patients can not the administration of Folic acid or Vitamin B12.\\r\\n\\r\\n          6. Before treatment with Pemetrexed.\\r\\n\\r\\n          7. Patients who can not swallow oral medication.\\r\\n\\r\\n          8. The most recent treatment with the clinical trial for the drug for 14 days prior to\\r\\n             enrollment.\\r\\n\\r\\n          9. Systemic chemotherapy within three weeks after the administration of the last before\\r\\n             the test treatment, radiation therapy patients who had been administered.\\r\\n\\r\\n         10. Except for the hair loss, it is induced before cancer treatment, all of toxicity in\\r\\n             progress (> CTCAE1 grade).\\r\\n\\r\\n         11. Upper GI bleeding within registration before 4 weeks of Bowel obstruction or CTCAE3 or\\r\\n             4 grade.\\r\\n\\r\\n         12. Subject who experienced a recent myocardial infarction, including severe/unstable\\r\\n             angina pectoris, coronary/peripheral artery bypass graft, uncontrolled hypertension,\\r\\n             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram\\r\\n             (ECG) abnormality, significant or uncontrolled cardiovascular disease CHF, and\\r\\n             cerebrovascular accident or transient ischemic attack, or seizure disorder in the past\\r\\n             year.\\r\\n      ', metadata={'nctid': 'NCT02588781', 'status': 'recruiting', 'diseases': \"['colorectal cancer']\", 'disease_category': 'cancer', 'drugs': \"['pemetrexed']\"}),\n",
       " Document(page_content=\"\\n        Main Inclusion Criteria:\\r\\n\\r\\n          1. Histology:\\r\\n\\r\\n               -  Phase Ib : Patient with histologically confirmed solid tumor\\r\\n\\r\\n               -  Phase II :\\r\\n\\r\\n                    -  Patients with histologically confirmed HER2 negative breast cancer\\r\\n                       (treatment by CP+JX-594), or triple negative (treatment by avelumab +\\r\\n                       CP+JX-594)\\r\\n\\r\\n                    -  Patients with histologically confirmed soft tissue sarcoma confirmed by the\\r\\n                       RRePS Network, b)Progressive disease or relapse, after standard therapy\\r\\n                       according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or\\r\\n                       MRI obtained at an interval less than 6 months in the period of 12 months\\r\\n                       prior to inclusion and confirmed by central review\\r\\n\\r\\n          2. Metastatic or unresectable locally advanced disease\\r\\n\\r\\n          3. Age ≥ 18 years\\r\\n\\r\\n          4. ECOG ≤ 1 (Phase Ib), ≤ 2 (Phase II JX+CP) and ≤ 1 (Phase II avelumab+JX+CP).\\r\\n\\r\\n          5. Life expectancy > 3 months,\\r\\n\\r\\n          6. Measurable disease according to RECIST v1.1 outside any previously irradiated field.\\r\\n             For patients treated by avelumab+JX+CP, at least one injectable site ≥ 2 cm and ≤ 8 cm\\r\\n             in diameter and one distant non-injected measurable site (target site)\\r\\n\\r\\n          7. At least three weeks since last chemotherapy, immunotherapy or any other\\r\\n             pharmacological treatment and/or radiotherapy.\\r\\n\\r\\n          8. Adequate hematological, renal, metabolic and hepatic functions.\\r\\n\\r\\n          9. Women of childbearing potential must have a negative serum pregnancy test before study\\r\\n             entry. Both women and men must agree to use a medically acceptable method of\\r\\n             contraception throughout the treatment period and for six months after discontinuation\\r\\n             of treatment.\\r\\n\\r\\n         10. Patients informed of risks regarding drug interactions: patients receiving any\\r\\n             substances that are inhibitors or inducers of CYP450 2B6 are ineligible\\r\\n\\r\\n         11. Voluntarily signed and dated written informed consent prior to any study specific\\r\\n             procedure.\\r\\n\\r\\n         12. Patients with a social security in compliance with the French law.\\r\\n\\r\\n        Main Exclusion Criteria:\\r\\n\\r\\n          1. Previous treatment with JX-594 or other vaccina vector based treatment or with\\r\\n             PD1/PDL1 antagonist for treatment by avelumab.\\r\\n\\r\\n          2. Concomitant diseases/conditions (non exhaustive list):\\r\\n\\r\\n               1. Clinically significant immunodeficiency, such as HIV or active Hepatite B or C\\r\\n\\r\\n               2. Any other major illness that, in the Investigator's judgment, will substantially\\r\\n                  increase the risk associated with the patient's participation in this study.\\r\\n\\r\\n               3. History of severe exfoliative skins condition requiring systemic treatment for\\r\\n                  more than 4 weeks in the last two years.\\r\\n\\r\\n               4. active autoimmune disease for patients treated by avelumab\\r\\n\\r\\n          3. Active central nervous system metastasis (CNS)\\r\\n\\r\\n          4. Participation to a study involving a medical or therapeutic intervention in the last\\r\\n             30 days.\\r\\n\\r\\n          5. Previous enrolment in the present study.\\r\\n\\r\\n          6. Patient unable to follow and comply with the study procedures because of any\\r\\n             geographical, social or psychological reasons.\\r\\n\\r\\n          7. Known hypersensitivity to any involved study drug or any of its formulation\\r\\n             components.\\r\\n\\r\\n          8. Use of steroids (any route of administration), interferon/pegylated interferon or\\r\\n             ribavirin that cannot be discontinued within 14 days prior to any JX-594 dose.\\r\\n\\r\\n          9. No prior malignancy except for the following: adequately treated basal or squamous\\r\\n             cell skin cancer, in situ cervical cancer, adequately treated Stage 1 or Stage 2\\r\\n             cancer from which the patient is currently in complete remission or any other cancer\\r\\n             from which the patient has been disease-free for 3 years.\\r\\n\\r\\n         10. Active cardiovascular disease, including but not limited to significant coronary\\r\\n             artery disease (e.g. requiring angioplasty or stenting) or congestive heart failure\\r\\n             within the preceding 12 months. (treatment by CP+JX)\\r\\n\\r\\n         11. Inability to suspend treatment with anti-hypertensive medication for 48 hours prior to\\r\\n             and 48 hours after all JX-594 treatments.\\r\\n\\r\\n         12. Pulse oximetry O2 saturation < 90% at rest on room air.\\r\\n\\r\\n         13. Experienced a severe systemic reaction or side-effect as result of previous smallpox\\r\\n             vaccination.\\r\\n\\r\\n         14. Cardiac disease: LVEF out of normal limits ; cumulative dose of anthracyclines in\\r\\n             excess of 450 mg/m²\\r\\n\\r\\n         15. Known urinary tract obstruction\\r\\n\\r\\n         16. Household contact exclusions for patients enrolled: children< 1 year old ; People with\\r\\n             skin disease (e.g., eczema, atopic dermatitis and related diseases…),\\r\\n             Immunocompromised hosts (severe deficiencies in cell-mediated immunity, including\\r\\n             AIDS, organ transplant recipients, hematologic malignancies)\\r\\n\\r\\n         17. Vaccination within 4 weeks of the first dose of study treatment and while on trial is\\r\\n             prohibited except for administration of inactivated vaccines.\\r\\n      \", metadata={'nctid': 'NCT02630368', 'status': 'recruiting', 'diseases': \"['solid tumors', 'soft-tissue sarcoma', 'breast cancer']\", 'disease_category': 'cancer', 'drugs': \"['cyclophosphamide and jx-594 dose escalation', 'cyclophosphamide and jx-594', 'cyclophosphamide', 'avelumab and jx-594 and cyclophosphamide']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Cytologically or histologically confirmed esophageal carcinoma;\\r\\n\\r\\n          2. ECOG performance status: 0-1;\\r\\n\\r\\n          3. No treatments prior to enrollment;\\r\\n\\r\\n          4. At least one measurable lesion on CT, MRI or esophageal barium exam;\\r\\n\\r\\n          5. Normal functions of heart, lung, liver, kidney and bone marrow;\\r\\n\\r\\n          6. Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl,\\r\\n             neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL;\\r\\n\\r\\n          7. Informed consent signed.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatments of chemotherapy or irradiation;\\r\\n\\r\\n          2. Poor bone marrow, liver and kidney functions, which would make chemotherapy\\r\\n             intolerable;\\r\\n\\r\\n          3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal\\r\\n             ulcer, fistula to mediastinum, or haematemesis;\\r\\n\\r\\n          4. Participating in other clinical trials;\\r\\n\\r\\n          5. Clinically significant and uncontrolled major medical conditions including but not\\r\\n             limited to: active uncontrolled infection, symptomatic congestive heart failure,\\r\\n             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation\\r\\n             that would limit compliance with study requirements; any medical condition, which in\\r\\n             the opinion of the study investigator places the subject at an unacceptably high risk\\r\\n             for toxicities;\\r\\n\\r\\n          6. The subject has had another active malignancy within the past five years except for\\r\\n             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of\\r\\n             the skin.\\r\\n      ', metadata={'nctid': 'NCT02716688', 'status': 'recruiting', 'diseases': \"['esophageal cancer', 's-1', 'radiotherapy']\", 'disease_category': 'cancer', 'drugs': \"['s-1']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed\\r\\n             by pathology review at MSK.\\r\\n\\r\\n          -  Patients will have relapsed at least once and returned to complete clinical remission\\r\\n             after additional chemotherapy. Interval surgery is permitted.\\r\\n\\r\\n          -  Complete clinical remission is defined as CA-125 within normal limits, examination and\\r\\n             CT or MRI without objective evidence of disease (non specific abnormalities are\\r\\n             permitted on radiologic imaging).\\r\\n\\r\\n          -  Patients may sign screening consent during recurrence or at time of remission if they\\r\\n             can start vaccine therapy within 4 months of completing chemotherapy.\\r\\n\\r\\n          -  Testing of patient's archived (paraffin embedded, unstained slides) or freshly\\r\\n             biopsied tumor nodules must be positive for WT1 (Cohort 1) or NY-ESO-1 (Cohort 2)\\r\\n             protein expression. WT1 expression: Immunohistochemical analysis will be performed\\r\\n             using the technique described by Dupont et al [58]. WT1 expression will be graded\\r\\n             according to an adaptation of the German Immunoreactive Score (IRS). Only tumors with\\r\\n             moderate to strong IRS scores (4-12) will be considered WT1 positive.\\r\\n\\r\\n          -  NY-ESO-1 expression: Tissue available from primary and/or recurrent disease will be\\r\\n             evaluated for tumor expression of NY-ESO-1 by immunohistochemical (IHC) and/or RT-PCR\\r\\n             analysis will be performed using the technique described by Jungbluth et al\\r\\n\\r\\n          -  Age ≥ 18 years\\r\\n\\r\\n          -  Karnofsky performance status ≥ 70%\\r\\n\\r\\n          -  Hematologic parameters: Absolute neutrophil count ≥ 1000/mcL, Platelets > 50 K/mcL.\\r\\n\\r\\n          -  Biochemical parameters: Total bilirubin ≤ 1.5 mg/dl, AST and ALT ≤ 2.5 x upper limits\\r\\n             of normal, Creatinine ≤ 1.5 mg/dl.\\r\\n\\r\\n          -  Patient of childbearing potential must have a negative serum pregnancy test prior to\\r\\n             study entry and must be practicing and effective form of birth control\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Pregnant or lactating women\\r\\n\\r\\n          -  Patients with active infection requiring systemic antibiotics, antiviral, or\\r\\n             antifungal treatments\\r\\n\\r\\n          -  Patients with a serious unstable medical illness or another active cancer.\\r\\n\\r\\n          -  Patients with a condition requiring systemic treatment with either corticosteroids\\r\\n             (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14\\r\\n             days of study drug administration. Inhaled or topical steroids and adrenal replacement\\r\\n             doses >10mg daily prednisone equivalents are permitted in the absence of active\\r\\n             autoimmune disease.\\r\\n\\r\\n          -  Patients with known history of testing positive for human immunodeficiency virus (HIV)\\r\\n             or known acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\n          -  Patients with known active hepatitis B virus or hepatitis C virus acute or chronic\\r\\n             infection.\\r\\n\\r\\n          -  Patients with active known or suspected autoimmune disease (treated hypothyroidism is\\r\\n             permitted to enroll)\\r\\n\\r\\n          -  Patients with active interstitial pneumonitis.\\r\\n      \", metadata={'nctid': 'NCT02737787', 'status': 'recruiting', 'diseases': \"['ovarian cancer', 'fallopian tube', 'primary peritoneal cancer', 'recurrent ovarian cancer']\", 'disease_category': 'cancer', 'drugs': \"['nivolumab']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Diagnosis of adenocarcinoma of the rectum\\r\\n\\r\\n          -  Age: 18-70 years old\\r\\n\\r\\n          -  Signed informed consent; able to comply with study and/or follow- up procedures\\r\\n\\r\\n          -  Stage of the primary tumor may be determined by ultrasound or MRI\\r\\n\\r\\n          -  Stage II (T3-4, N0 [N0 is defined as all imaged lymph nodes < 1.0 cm]) OR stage III\\r\\n             (T1-4, N1-2 [with the definition of a clinically positive lymph node being any node ≥\\r\\n             1.0 cm]\\r\\n\\r\\n          -  Tumor palpable by digital rectal exam OR accessible by proctoscope or sigmoidoscope\\r\\n\\r\\n          -  Distal border of the tumor must be located < 12 cm from the anal verge\\r\\n\\r\\n          -  Tumor amenable to curative resection\\r\\n\\r\\n          -  Adequate bone marrow, hepatic and renal function as assessed by the following\\r\\n             laboratory requirements conducted within 7 days of starting study treatment:\\r\\n\\r\\n          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet\\r\\n             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.\\r\\n\\r\\n          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).\\r\\n\\r\\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\\r\\n\\r\\n          -  Alkaline phosphatase limit ≤ 5x ULN.\\r\\n\\r\\n          -  Amylase and lipase ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Serum creatinine ≤ 1.5 x the ULN.\\r\\n\\r\\n          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.\\r\\n\\r\\n          -  No renal disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  ECOG status: 0～1\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.\\r\\n\\r\\n          -  No More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  More than 4 weeks since prior participation in any investigational drug study\\r\\n\\r\\n          -  Clear indication of involvement of the pelvic side walls by imaging\\r\\n\\r\\n          -  With distant metastasis\\r\\n\\r\\n          -  History of invasive rectal malignancy, regardless of disease-free interval\\r\\n\\r\\n          -  Fertile patients must use effective contraception\\r\\n\\r\\n          -  Uncontrolled hypertension\\r\\n\\r\\n          -  Cardiovascular disease that would preclude study treatment or follow-up\\r\\n\\r\\n          -  Lack of upper gastrointestinal tract integrity or malabsorption syndrome，active upper\\r\\n             gastrointestinal tract bleeding\\r\\n\\r\\n          -  Synchronous colon cancer\\r\\n\\r\\n          -  Pregnant or nursing, Fertile patients do not use effective contraception\\r\\n\\r\\n          -  Other malignancy within the past 5 years except effectively treated squamous cell or\\r\\n             basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or\\r\\n             carcinoma in situ of the colon or rectum\\r\\n\\r\\n          -  No psychiatric or addictive disorders, or other conditions that, in the opinion of the\\r\\n             investigator, would preclude study participation\\r\\n\\r\\n          -  patients refused to signed informed consent.\\r\\n      ', metadata={'nctid': 'NCT02887313', 'status': 'recruiting', 'diseases': \"['rectal cancer']\", 'disease_category': 'cancer', 'drugs': \"['mfolfox6']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Able to understand and comply with the study procedures, understand the risks involved\\r\\n             in the study, and provide written informed consent before the first study-specific\\r\\n             procedure; specifically able to comply with the PK assessment schedule during the\\r\\n             first 2 treatment cycles.\\r\\n\\r\\n          2. Men or women ≥18 years who are candidates to receive IV decitabine according to FDA or\\r\\n             European Medicines Agency (EMA) approved indications:\\r\\n\\r\\n               1. In North America: Participants with MDS previously treated or untreated with de\\r\\n                  novo or secondary MDS, including all French-American-British subtypes (refractory\\r\\n                  anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess\\r\\n                  blasts, refractory anemia with excess blasts in transformation, and chronic\\r\\n                  myelomonocytic leukemia [CMML]), and subjects with MDS International Prognostic\\r\\n                  Scoring System (IPSS) int-1, -2, or high-risk MDS.\\r\\n\\r\\n               2. In Europe: Participants with de novo or secondary AML, as defined by the World\\r\\n                  Health Organization (WHO) criteria, who are not candidates for standard induction\\r\\n                  chemotherapy.\\r\\n\\r\\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n          4. Adequate organ function defined as follows:\\r\\n\\r\\n               1. Hepatic: Total or direct bilirubin ≤2 × upper limit of normal (ULN); aspartate\\r\\n                  transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine\\r\\n                  transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤2.5 × ULN.\\r\\n\\r\\n               2. Renal: serum creatinine ≤1.5 × ULN or calculated creatinine clearance or\\r\\n                  glomerular filtration rate >50 mL/min/1.73 m2 for subjects with creatinine levels\\r\\n                  above institutional normal.\\r\\n\\r\\n          5. No major surgery within 30 days of first study treatment.\\r\\n\\r\\n          6. Life expectancy of at least 3 months.\\r\\n\\r\\n          7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a\\r\\n             negative pregnancy test at screening. Women of non-childbearing potential are those\\r\\n             who have had a hysterectomy or bilateral oophorectomy, or who have completed\\r\\n             menopause, defined as no menses for at least 1 year AND either age ≥65 years or\\r\\n             follicle-stimulating hormone levels in the menopausal range.\\r\\n\\r\\n          8. Subjects and their partners with reproductive potential must agree to use effective\\r\\n             contraceptive measures during the study and for 3 months after the last dose of study\\r\\n             treatment. Effective contraception includes methods such as oral contraceptives or\\r\\n             double-barrier method (eg, use of a condom AND diaphragm, with spermicide).\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Prior treatment with more than 1 cycle of azacitidine or decitabine. Prior cytotoxic\\r\\n             chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC)\\r\\n             counts.\\r\\n\\r\\n          2. Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia,\\r\\n             sepsis, or systemic infection in the 30 days before screening.\\r\\n\\r\\n          3. Treatment with any investigational drug or therapy within 2 weeks of study treatment,\\r\\n             or 5 half-lives, whichever is longer, before the first dose of study treatment, or\\r\\n             ongoing clinically significant adverse events (AEs) from previous treatment.\\r\\n\\r\\n          4. Cytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose\\r\\n             of study treatment.\\r\\n\\r\\n          5. Concurrent MDS therapies, including lenalidomide, erythropoietin,\\r\\n             cyclosporine/tacrolimus, granulocyte-colony stimulating factor (G-CSF),\\r\\n             granulocyte-macrophage colony-stimulating factor, etc. (Prior treatment with these\\r\\n             agents is permitted, provided that completion is at least 1 week before the first dose\\r\\n             of study treatment.)\\r\\n\\r\\n          6. Poor medical risk because of other conditions such as uncontrolled systemic diseases,\\r\\n             active uncontrolled infections, or comorbidities that may put the patient at risk of\\r\\n             not being able to complete at least 2 cycles of treatment.\\r\\n\\r\\n          7. Known significant mental illness or other condition, such as active alcohol or other\\r\\n             substance abuse or addiction, that in the opinion of the investigator predisposes the\\r\\n             subject to high risk of noncompliance with the protocol.\\r\\n\\r\\n          8. Rapidly progressive or highly proliferative disease (total white blood cell count of\\r\\n             >15 × 10^9/L) or other criteria that render the subject at high risk of requiring\\r\\n             intensive cytotoxic chemotherapy within the next 3 months.\\r\\n\\r\\n          9. Life-threatening illness or severe organ system dysfunction, such as uncontrolled\\r\\n             congestive heart failure or chronic obstructive pulmonary disease, or other reasons\\r\\n             including laboratory abnormalities, which, in the investigator's opinion, could\\r\\n             compromise the subject's safety, interfere with the absorption or metabolism of\\r\\n             ASTX727, or compromise completion of the study or integrity of the study outcomes.\\r\\n\\r\\n         10. Prior malignancy, except for adequately treated basal cell or squamous cell skin\\r\\n             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with\\r\\n             hormone therapy, or other cancer from which the subject has been disease free for at\\r\\n             least 2 years.\\r\\n      \", metadata={'nctid': 'NCT03306264', 'status': 'recruiting', 'diseases': \"['myelodysplastic syndromes', 'chronic myelomonocytic leukemia', 'acute myeloid leukemia']\", 'disease_category': 'leukemia', 'drugs': \"['astx727', 'dacogen']\"}),\n",
       " Document(page_content=\"\\n        Inclusion Criteria:\\r\\n\\r\\n          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).\\r\\n\\r\\n          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved\\r\\n             stable disease or a partial response.\\r\\n\\r\\n          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR\\r\\n             mutant-positive for 3 months and achieved stable disease, partial response or\\r\\n             completely response.\\r\\n\\r\\n          4. Age 18 to 75 years old.\\r\\n\\r\\n          5. Patients must have measurable disease at baseline.\\r\\n\\r\\n          6. The amount of metastatic focus <5.\\r\\n\\r\\n          7. ECOG score 0-2\\r\\n\\r\\n          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.\\r\\n\\r\\n          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)\\r\\n\\r\\n         10. Patients must provide written informed consent to participate in the study.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          1. Patients who previously received radiotherapy to the primary site.\\r\\n\\r\\n          2. Patient can't tolerate radiotherapy or targeted therapy;\\r\\n\\r\\n          3. Pregnant or nursing women\\r\\n      \", metadata={'nctid': 'NCT03595644', 'status': 'recruiting', 'diseases': \"['stage iv non-small cell lung cancer']\", 'disease_category': 'cancer', 'drugs': \"['tki']\"}),\n",
       " Document(page_content='\\n        Inclusion Criteria:\\r\\n\\r\\n          -  Patients of both sexes\\r\\n\\r\\n          -  Eighteen years of age and older\\r\\n\\r\\n          -  Clinical diagnosis of Generalized Anxiety Disorder\\r\\n\\r\\n          -  Eighteen points or more on Hamilton Anxiety Scale\\r\\n\\r\\n          -  Without previous treatment for this disease (for at least one month before).\\r\\n\\r\\n          -  In case of being women of reproductive age, who are not pregnant or lactating.\\r\\n\\r\\n          -  To sign an informed consent letter of participation in the investigation.\\r\\n\\r\\n        Exclusion Criteria:\\r\\n\\r\\n          -  Patients who have treatment for their condition\\r\\n\\r\\n          -  Patients who have another mental disorder added\\r\\n\\r\\n          -  Patients with alcoholism, smoking or drug addiction\\r\\n\\r\\n          -  Patients who live alone\\r\\n\\r\\n          -  Ingest of drugs for insomnia\\r\\n\\r\\n          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group\\r\\n\\r\\n          -  Patients with epilepsy\\r\\n\\r\\n          -  Patients who operate dangerous machinery\\r\\n\\r\\n          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long\\r\\n             time.\\r\\n      ', metadata={'nctid': 'NCT03702803', 'status': 'recruiting', 'diseases': \"['generalized anxiety disorder']\", 'disease_category': 'mental_health', 'drugs': \"['alprazolam 1mg']\"})]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from helper_functions import disease_map\n",
    "\n",
    "vstore_delete = False\n",
    "\n",
    "trial_docs = []\n",
    "for i, row in df_trials.iterrows():\n",
    "    disease = disease_map(row['diseases'])\n",
    "    if disease == 'other_conditions':\n",
    "        continue\n",
    "    doc = Document(\n",
    "        page_content=row['criteria'],\n",
    "        metadata={\n",
    "            \"nctid\": row['nctid'],\n",
    "            \"status\": row['status'],\n",
    "            # \"why_stop\": row['why_stop'],\n",
    "            # \"label\": row['label'],\n",
    "            # \"phase\": row['phase'],\n",
    "            \"diseases\": str(row['diseases']),\n",
    "            \"disease_category\": disease[0],\n",
    "            \"drugs\": row['drugs'],            \n",
    "        }\n",
    "    )\n",
    "    trial_docs.append(doc)\n",
    "# trial_docs\n",
    "\n",
    "print(trial_docs[0].metadata)\n",
    "\n",
    "list_remove = set()\n",
    "for i, doc in enumerate(trial_docs):\n",
    "    if len(doc.page_content)>10000:\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "    if doc.metadata['disease_category'] == 'other_conditions':\n",
    "        list_remove.add(i)\n",
    "        # print(doc.metadata)\n",
    "# remove list_remove indexes from trial_docs\n",
    "trial_docs = [doc for i, doc in enumerate(trial_docs) if i not in list_remove]\n",
    "\n",
    "# print(len(trial_docs[11].page_content))\n",
    "# trial_docs.pop(11)\n",
    "\n",
    "persistent_client = chromadb.PersistentClient(path = chromadb_path)\n",
    "\n",
    "if vstore_delete == True:\n",
    "    vectorstore_trials.delete_collection()\n",
    "    trials_vstore_created = False\n",
    "    vstore_delete = False\n",
    "    print(\"vstore deleted\")\n",
    "\n",
    "vectorstore_trials = Chroma(\n",
    "    client=persistent_client,\n",
    "    collection_name=trial_collection,\n",
    "    embedding_function=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                            inference_mode='local'),\n",
    ")\n",
    "if vectorstore_trials._collection.count() == 0:\n",
    "    vectorstore_trials = Chroma.from_documents(\n",
    "        documents=trial_docs,\n",
    "        client=persistent_client,\n",
    "        collection_name=trial_collection,\n",
    "        # persist_directory=chromadb_path,\n",
    "        embedding=NomicEmbeddings(model=\"nomic-embed-text-v1.5\",\n",
    "                                inference_mode='local'),\n",
    "    )\n",
    "    trials_vstore_created = True\n",
    "    print(\"Vectorstore is created now\")\n",
    "else:\n",
    "    print(\"Loading the vectorstore from persistent client\")\n",
    "\n",
    "print(vectorstore_trials._collection.count())\n",
    "trial_docs\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Tools:\n",
    "Here we define some tools that the agent needs to use for evaluation of the patient, general policies, and clinic trials."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Patient Data Extractor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import tool\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "def get_patient_data(patient_id: int) -> dict:\n",
    "    \"\"\"Fetch all fields for the patient based on the given patient_id as an integer.\n",
    "\n",
    "    Returns:\n",
    "        A dictionary containing the patient's medical history.        \n",
    "    \"\"\"    \n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()    \n",
    "    query = 'SELECT * FROM patients WHERE patient_id=?'\n",
    "    cursor.execute(query, (patient_id,))\n",
    "    patient_data = cursor.fetchone()\n",
    "    # rows = cursor.fetchall()\n",
    "    column_names = [column[0] for column in cursor.description]\n",
    "    conn.close()\n",
    "    if patient_data is None:\n",
    "        return None\n",
    "    else:    \n",
    "        results = dict(zip(column_names, patient_data))    \n",
    "    return results\n",
    "\n",
    "# Also possible to add a new patient\n",
    "def add_patient_data(patient_data: dict):    \n",
    "    \"\"\"Adds a new patient to the SQLite database.\"\"\"\n",
    "    \n",
    "    name = patient_data['name']\n",
    "    age = patient_data['age']\n",
    "    medical_history = patient_data['medical_history']\n",
    "    previous_trials = patient_data['previous_trials']\n",
    "    trial_status = patient_data['trial_status']\n",
    "    last_trial_dates = patient_data['last_trial_dates']\n",
    "\n",
    "    conn = sqlite3.connect(db)\n",
    "    cursor = conn.cursor()\n",
    "    \n",
    "    # Insert the new patient data into the database\n",
    "    cursor.execute('''\n",
    "    INSERT INTO patients (name, age, medical_history, previous_trials, trial_status, last_trial_dates)\n",
    "    VALUES (?, ?, ?, ?, ?, ?)\n",
    "    ''', (name, age, medical_history, previous_trials, trial_status, last_trial_dates))\n",
    "    \n",
    "    conn.commit()\n",
    "    conn.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_id': 1,\n",
       " 'name': 'James Anderson',\n",
       " 'age': 75,\n",
       " 'medical_history': 'Heart Disease',\n",
       " 'previous_trials': None,\n",
       " 'trial_status': None,\n",
       " 'trial_completion_date': None}"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_patient_id = 1\n",
    "patient_data = get_patient_data(sample_patient_id)\n",
    "patient_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Maker"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "parser = StrOutputParser()\n",
    "prompt_profile = PromptTemplate(\n",
    "    template=\"\"\"\n",
    "    You are the Clinical Research Coordinator in the screening phase of a clinical trial. \n",
    "    Use the following patient data to write the patient profile for the screening phase.\n",
    "    The patient profile is a summary of the patient's information in continuous text form.    \n",
    "    If they had no previous trial participation, exclude trial status and trial completion date.\\n\n",
    "    Do not ignore any available information.\\n \n",
    "    Also suggest medical trials that can be related to patient's disease history.\\n    \n",
    "    Write the patient profile in 3 to 4 short sentences.\\n\\n\n",
    "    {patient_data}\"\"\",\n",
    "    input_variables=[\"patient_data\"],\n",
    ")\n",
    "# In a separate section of the profile, also suggest medical trial categories related to patient's disease history.\\n    \n",
    "# model = ChatOpenAI(temperature = 0.0, model=modelID)\n",
    "\n",
    "chain_profile = prompt_profile | model | parser\n",
    "# to preserve the patient's private information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('Patient is a 75-year-old individual with a medical history of Heart Disease. '\n",
      " 'They have not participated in any previous clinical trials. Given their '\n",
      " 'history of Heart Disease, potential medical trials that could be related to '\n",
      " 'their condition include those focusing on cardiovascular health and '\n",
      " 'treatment options for heart-related issues.')\n"
     ]
    }
   ],
   "source": [
    "# to preserve the patient's private information\n",
    "if patient_data.get('name'):\n",
    "    del patient_data['patient_id']\n",
    "    del patient_data['name']\n",
    "\n",
    "patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "nprint(patient_profile) # patient_profile"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policy Retriever\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "5\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 6. **Special Considerations**\\n   - **Pregnancy and Nursing**: Pregnant or nursing women are excluded unless the trial is specifically designed for this population.\\n   - **Genetic Testing**: Trials involving genetic testing must have explicit consent from patients for genetic data collection and analysis.\\n   - **Patient Monitoring**: Patients must agree to regular monitoring and follow-up visits as specified by the trial protocol.\\n   - **BMI Restrictions**: Patients with a BMI outside the range of 18.5-35 may be excluded unless otherwise specified.\\n   - **Comorbid Conditions**: Patients with multiple comorbid conditions that may interfere with the study outcomes are excluded.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}),\n",
       " Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]"
      ]
     },
     "execution_count": 112,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retriever_policy = vectorstore.as_retriever(search_kwargs={\"k\": n_retrieved_policies})\n",
    "\n",
    "# sample policy retrieval\n",
    "docs_retrieved = retriever_policy.get_relevant_documents(patient_profile)\n",
    "print(len(docs_retrieved))\n",
    "doc_txt = docs_retrieved[0].page_content\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policies to Questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Policies --> questions\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "\n",
    "prompt_rps = PromptTemplate(\n",
    "    template=\"\"\" You are a Principal Investigator (PI) for clinical trials. \n",
    "        The following document contains a policy document about participation in clinial trials:\n",
    "        \\n\\n{policy}\\n\\b\n",
    "\n",
    "        Your task is to rephrase each single policy from the document above into a single yes/no question. \n",
    "        Form each question so that a yes answer indicates the patient's ineligibility.\n",
    "        Do not create more questions than given number of policies.\n",
    "\n",
    "        Example: Patients who have had accidents in the past 10 months are not eligible\n",
    "        rephrased: Did patient have an accident in the past 10 months?\n",
    "\n",
    "        Example: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\n",
    "        rephrased: Did patient have active tuberculosis, hepatitis B or C, or HIV?\n",
    "        \"\"\",\n",
    "    input_variables=[\"policy\"],\n",
    ")\n",
    "\n",
    "class policy_relevance(BaseModel):\n",
    "    \"policy relevance score\"\n",
    "\n",
    "    relevant: str = Field(description=\"is policy relevant? 'yes' or 'no'.\")\n",
    "    reason: str\n",
    "\n",
    "parser = StrOutputParser()\n",
    "\n",
    "policy_rps_chain = prompt_rps | model | parser\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('1. Is the patient under 18 or over 75 years old?\\n'\n",
      " \"2. Is the patient's gender restricted by the trial protocol?\\n\"\n",
      " '3. Has the patient not provided informed consent?\\n'\n",
      " '4. Is the patient not a resident of the country where the trial is '\n",
      " 'conducted?\\n'\n",
      " '5. Does the patient not have valid health insurance coverage?')\n"
     ]
    }
   ],
   "source": [
    "\n",
    "policy = docs_retrieved[0].page_content\n",
    "policy_qs = policy_rps_chain.invoke({\"policy\": policy})\n",
    "nprint(policy_qs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Policy Evaluator with Python Tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.tools import StructuredTool\n",
    "from datetime import date, datetime\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langgraph.prebuilt import create_react_agent\n",
    "\n",
    "\n",
    "def policy_tools(policy_qs: str, patient_profile: str):\n",
    "    system_message = \"\"\"\n",
    "    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\n",
    "    You are asked to compare the patient profile document to the institution policy questions.\n",
    "    You must determine if the patient is eligible based on the following documnents.\n",
    "\n",
    "    \\n #### Here is the patient profile document: \\n {patient_profile}\\n\\n\n",
    "\n",
    "    If the answer to any policy question is yes, then the patient is not eligible.\\n\n",
    "    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\n",
    "\n",
    "    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\n",
    "    If the patient is not eligible then also include the reason in your response.\n",
    "\n",
    "    You have access to the following tools:\n",
    "    {tool_names}\n",
    "    \"\"\"\n",
    "\n",
    "    prompt = ChatPromptTemplate.from_messages(\n",
    "        [\n",
    "            (\"system\", system_message),\n",
    "            (\"human\", \"{input}\"),\n",
    "            # Placeholders fill up a **list** of messages\n",
    "            (\"placeholder\", \"{agent_scratchpad}\"),\n",
    "        ]\n",
    "    )\n",
    "\n",
    "    class CalculatorInput(BaseModel):\n",
    "        num1: float = Field(description=\"first number\")\n",
    "        num2: float = Field(description=\"second number\")\n",
    "\n",
    "    def multiply(num1: float, num2: float) -> float:\n",
    "        \"multiplies two input numbers together, num1 and num2\"\n",
    "        return (num1 * num2)\n",
    "\n",
    "    multiply_tool = StructuredTool.from_function(\n",
    "        func=multiply,\n",
    "        name=\"multiply\",\n",
    "        description=\"multiply numbers\",\n",
    "        args_schema=CalculatorInput,\n",
    "        # return_direct=True,    \n",
    "    )\n",
    "\n",
    "    @tool(\"date_today-tool\")\n",
    "    def date_today() -> datetime.date:\n",
    "        \"returns today date\"\n",
    "        return datetime.today().date()    \n",
    "\n",
    "    def date_difference(date1: date, date2: date) -> int:\n",
    "        \"The number of months date1 is before date2\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        month_difference = (date2.year - date1.year) * 12 + date2.month - date1.month\n",
    "        return f'{month_difference} months'\n",
    "\n",
    "    class dates(BaseModel):\n",
    "        date1: date = Field(description=\"first date\")\n",
    "        date2: date = Field(description=\"second date\")\n",
    "\n",
    "    date_difference_tool = StructuredTool.from_function(\n",
    "        func=date_difference,\n",
    "        name=\"date_difference\",\n",
    "        description=\"The number of months first date is before second date\",\n",
    "        args_schema=dates,\n",
    "        # return_direct=True,    \n",
    "    )\n",
    "\n",
    "    class date_class(BaseModel):\n",
    "        date: str = Field(description=\"A date string in the format YYYY-MM-DD\")    \n",
    "\n",
    "    @tool(\"date_convert-tool\", args_schema=date_class)\n",
    "    def date_convert(date: str) -> date:\n",
    "        \"Converts a date string to a date object\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        date = datetime.strptime(date, \"%Y-%m-%d\").date()\n",
    "        return date\n",
    "\n",
    "    @tool(\"date_split-tool\", args_schema=date_class)\n",
    "    def date_split(date: str) -> date:\n",
    "        \"Extracts the year and month from a date string\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        date = datetime.strptime(date, \"%Y-%m-%d\").date()\n",
    "        year = date.year\n",
    "        month = date.month\n",
    "        return f'year: {year}, month: {month}'\n",
    "\n",
    "    @tool(\"number_comparison-tool\", args_schema=CalculatorInput)\n",
    "    def number_compare(num1: float, num2: float) -> bool:\n",
    "        \"Determines if first number is less than the second number\"\n",
    "        # \"How many months before date2 is date1?\"\n",
    "        num1_less_num1 = num1 < num2\n",
    "        return num1_less_num1\n",
    "\n",
    "    tools = [multiply_tool, date_today, date_difference_tool, date_split, number_compare]\n",
    "\n",
    "    tool_names=\", \".join([tool.name for tool in tools])\n",
    "    prompt = prompt.partial(tool_names=tool_names)\n",
    "    prompt = prompt.partial(patient_profile=patient_profile)\n",
    "\n",
    "    model_agent = ChatOpenAI(temperature=0, model=\"gpt-4o\")\n",
    "    react_agent = create_react_agent(model_agent, tools, prompt, debug=False)\n",
    "\n",
    "    message = f\"\"\" Here are the policy questions: \\n{policy_qs}\"\"\"\n",
    "    messages = react_agent.invoke({\"messages\": [(\"human\", message)]})\n",
    "    result = messages[\"messages\"][-1].content    \n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"messages\": [\n",
      "    [\n",
      "      \"human\",\n",
      "      \" Here are the policy questions: \\n\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n\"\n",
      "    ]\n",
      "  ]\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:__start__] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"messages\": [\n",
      "    [\n",
      "      \"human\",\n",
      "      \" Here are the policy questions: \\n\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n\"\n",
      "    ]\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:__start__] [41ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"messages\": [\n",
      "    [\n",
      "      \"human\",\n",
      "      \" Here are the policy questions: \\n\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n\"\n",
      "    ]\n",
      "  ]\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > prompt:ChatPromptTemplate] Entering Prompt run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > prompt:ChatPromptTemplate] [43ms] Exiting Prompt run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatOpenAI] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n Patient is a 69-year-old individual with a medical history of lymphoblastic leukemia. They have previously participated in the clinical trial NCT06562807, which is currently ongoing. Given their history of lymphoblastic leukemia, the patient may be eligible for clinical trials focusing on leukemia treatments or immunotherapy.\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman: [HumanMessage(content=' Here are the policy questions: \\\\n\\\\n#### 1. **General Eligibility Criteria**\\\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\\\n', id='b57efcec-038e-46f7-939b-ff4dce1d065c')]\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatOpenAI] [1.56s] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"tool_calls\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"\",\n",
      "            \"additional_kwargs\": {\n",
      "              \"tool_calls\": [\n",
      "                {\n",
      "                  \"id\": \"call_J4Zm6BKkkx12UFgB0qY2wq1E\",\n",
      "                  \"function\": {\n",
      "                    \"arguments\": \"{}\",\n",
      "                    \"name\": \"date_today-tool\"\n",
      "                  },\n",
      "                  \"type\": \"function\"\n",
      "                },\n",
      "                {\n",
      "                  \"id\": \"call_4qjyoVynZlwAuhdcEgoUaLRL\",\n",
      "                  \"function\": {\n",
      "                    \"arguments\": \"{\\\"date\\\": \\\"2023-10-01\\\"}\",\n",
      "                    \"name\": \"date_split-tool\"\n",
      "                  },\n",
      "                  \"type\": \"function\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 48,\n",
      "                \"prompt_tokens\": 569,\n",
      "                \"total_tokens\": 617\n",
      "              },\n",
      "              \"model_name\": \"gpt-4o\",\n",
      "              \"system_fingerprint\": \"fp_4008e3b719\",\n",
      "              \"finish_reason\": \"tool_calls\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run-ecb472d0-3822-4531-8f31-28aabf8ff4b6-0\",\n",
      "            \"tool_calls\": [\n",
      "              {\n",
      "                \"name\": \"date_today-tool\",\n",
      "                \"args\": {},\n",
      "                \"id\": \"call_J4Zm6BKkkx12UFgB0qY2wq1E\"\n",
      "              },\n",
      "              {\n",
      "                \"name\": \"date_split-tool\",\n",
      "                \"args\": {\n",
      "                  \"date\": \"2023-10-01\"\n",
      "                },\n",
      "                \"id\": \"call_4qjyoVynZlwAuhdcEgoUaLRL\"\n",
      "              }\n",
      "            ],\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 569,\n",
      "              \"output_tokens\": 48,\n",
      "              \"total_tokens\": 617\n",
      "            },\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 48,\n",
      "      \"prompt_tokens\": 569,\n",
      "      \"total_tokens\": 617\n",
      "    },\n",
      "    \"model_name\": \"gpt-4o\",\n",
      "    \"system_fingerprint\": \"fp_4008e3b719\"\n",
      "  },\n",
      "  \"run\": null\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [1.65s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [1.69s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<agent,messages>] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<agent,messages>] [100ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [76ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"continue\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<branch:agent:should_continue:tools>] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<branch:agent:should_continue:tools>] [41ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [1.96s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[tool/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_today-tool] Entering Tool run with input:\n",
      "\u001b[0m\"{}\"\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:langchain_core.callbacks.manager:Error in ConsoleCallbackHandler.on_tool_end callback: AttributeError(\"'datetime.date' object has no attribute 'strip'\")\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[32;1m\u001b[1;3m[tool/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_split-tool] Entering Tool run with input:\n",
      "\u001b[0m\"{'date': '2023-10-01'}\"\n",
      "\u001b[36;1m\u001b[1;3m[tool/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > tool:date_split-tool] [42ms] Exiting Tool run with output:\n",
      "\u001b[0m\"year: 2023, month: 10\"\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > chain:ChannelWrite<tools,messages>] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools > chain:ChannelWrite<tools,messages>] [43ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:tools] [173ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > prompt:ChatPromptTemplate] Entering Prompt run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > prompt:ChatPromptTemplate] [86ms] Exiting Prompt run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatOpenAI] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"System: \\n    You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n    You are asked to compare the patient profile document to the institution policy questions.\\n    You must determine if the patient is eligible based on the following documnents.\\n\\n    \\n #### Here is the patient profile document: \\n Patient is a 69-year-old individual with a medical history of lymphoblastic leukemia. They have previously participated in the clinical trial NCT06562807, which is currently ongoing. Given their history of lymphoblastic leukemia, the patient may be eligible for clinical trials focusing on leukemia treatments or immunotherapy.\\n\\n\\n\\n    If the answer to any policy question is yes, then the patient is not eligible.\\n\\n    If the answer to the question is not provided in the patient profile, answer 'no'.\\n\\n\\n    Give a binary 'yes' or 'no' score in the response to indicate whether the patient is eligible according to the given policy ONLY.\\n    If the patient is not eligible then also include the reason in your response.\\n\\n    You have access to the following tools:\\n    multiply, date_today-tool, date_difference, date_split-tool, number_comparison-tool\\n    \\nHuman: [HumanMessage(content=' Here are the policy questions: \\\\n\\\\n#### 1. **General Eligibility Criteria**\\\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\\\n', id='b57efcec-038e-46f7-939b-ff4dce1d065c'), AIMessage(content='', additional_kwargs={'tool_calls': [{'id': 'call_J4Zm6BKkkx12UFgB0qY2wq1E', 'function': {'arguments': '{}', 'name': 'date_today-tool'}, 'type': 'function'}, {'id': 'call_4qjyoVynZlwAuhdcEgoUaLRL', 'function': {'arguments': '{\\\"date\\\": \\\"2023-10-01\\\"}', 'name': 'date_split-tool'}, 'type': 'function'}]}, response_metadata={'token_usage': {'completion_tokens': 48, 'prompt_tokens': 569, 'total_tokens': 617}, 'model_name': 'gpt-4o', 'system_fingerprint': 'fp_4008e3b719', 'finish_reason': 'tool_calls', 'logprobs': None}, id='run-ecb472d0-3822-4531-8f31-28aabf8ff4b6-0', tool_calls=[{'name': 'date_today-tool', 'args': {}, 'id': 'call_J4Zm6BKkkx12UFgB0qY2wq1E'}, {'name': 'date_split-tool', 'args': {'date': '2023-10-01'}, 'id': 'call_4qjyoVynZlwAuhdcEgoUaLRL'}], usage_metadata={'input_tokens': 569, 'output_tokens': 48, 'total_tokens': 617}), ToolMessage(content='2024-07-08', name='date_today-tool', id='79190a93-9f61-4718-9447-1cbc7bfda1f8', tool_call_id='call_J4Zm6BKkkx12UFgB0qY2wq1E'), ToolMessage(content='year: 2023, month: 10', name='date_split-tool', id='4a5df3eb-5015-4064-beba-1476a73cddd6', tool_call_id='call_4qjyoVynZlwAuhdcEgoUaLRL')]\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence > llm:ChatOpenAI] [2.98s] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n     - **Answer**: No\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n     - **Answer**: No\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n     - **Answer**: No\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n     - **Answer**: No\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n     - **Answer**: No\\n\\nBased on the provided policy questions and the patient profile, the patient is **eligible** for the clinical trial.\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"stop\",\n",
      "          \"logprobs\": null\n",
      "        },\n",
      "        \"type\": \"ChatGeneration\",\n",
      "        \"message\": {\n",
      "          \"lc\": 1,\n",
      "          \"type\": \"constructor\",\n",
      "          \"id\": [\n",
      "            \"langchain\",\n",
      "            \"schema\",\n",
      "            \"messages\",\n",
      "            \"AIMessage\"\n",
      "          ],\n",
      "          \"kwargs\": {\n",
      "            \"content\": \"#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n     - **Answer**: No\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n     - **Answer**: No\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n     - **Answer**: No\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n     - **Answer**: No\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n     - **Answer**: No\\n\\nBased on the provided policy questions and the patient profile, the patient is **eligible** for the clinical trial.\",\n",
      "            \"response_metadata\": {\n",
      "              \"token_usage\": {\n",
      "                \"completion_tokens\": 159,\n",
      "                \"prompt_tokens\": 1028,\n",
      "                \"total_tokens\": 1187\n",
      "              },\n",
      "              \"model_name\": \"gpt-4o\",\n",
      "              \"system_fingerprint\": \"fp_ce0793330f\",\n",
      "              \"finish_reason\": \"stop\",\n",
      "              \"logprobs\": null\n",
      "            },\n",
      "            \"type\": \"ai\",\n",
      "            \"id\": \"run-01d679d3-4c87-43f0-bf4a-a62500c0ce20-0\",\n",
      "            \"usage_metadata\": {\n",
      "              \"input_tokens\": 1028,\n",
      "              \"output_tokens\": 159,\n",
      "              \"total_tokens\": 1187\n",
      "            },\n",
      "            \"tool_calls\": [],\n",
      "            \"invalid_tool_calls\": []\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": {\n",
      "    \"token_usage\": {\n",
      "      \"completion_tokens\": 159,\n",
      "      \"prompt_tokens\": 1028,\n",
      "      \"total_tokens\": 1187\n",
      "    },\n",
      "    \"model_name\": \"gpt-4o\",\n",
      "    \"system_fingerprint\": \"fp_ce0793330f\"\n",
      "  },\n",
      "  \"run\": null\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model > chain:RunnableSequence] [3.11s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:call_model] [3.16s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<agent,messages>] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:ChannelWrite<agent,messages>] [84ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent > chain:should_continue] [46ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output\": \"end\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph > chain:agent] [3.33s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:LangGraph] [5.55s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "('#### 1. **General Eligibility Criteria**\\n'\n",
      " '   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n'\n",
      " '     - **Answer**: No\\n'\n",
      " '   - **Gender**: No restrictions unless specified by the trial protocol.\\n'\n",
      " '     - **Answer**: No\\n'\n",
      " '   - **Informed Consent**: All patients must provide informed consent prior '\n",
      " 'to participation.\\n'\n",
      " '     - **Answer**: No\\n'\n",
      " '   - **Residency**: Patients must be residents of the country where the '\n",
      " 'trial is conducted.\\n'\n",
      " '     - **Answer**: No\\n'\n",
      " '   - **Health Insurance**: Patients must have valid health insurance '\n",
      " 'coverage.\\n'\n",
      " '     - **Answer**: No\\n'\n",
      " '\\n'\n",
      " 'Based on the provided policy questions and the patient profile, the patient '\n",
      " 'is **eligible** for the clinical trial.')\n"
     ]
    }
   ],
   "source": [
    "# sample policy evaluation\n",
    "import langchain\n",
    "langchain.debug = True\n",
    "policy = docs_retrieved[0].page_content\n",
    "# nprint(policy)\n",
    "result = policy_tools(policy, patient_profile)\n",
    "nprint(result)\n",
    "langchain.debug = False"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Trials Retriever \n",
    "\n",
    "We use SelfQueryRetriever module that also uses metadata information. This retrival can quickly find relevant trials based on metadata such as disease category, drug names, etc.   \n",
    "The value of such retrival becomes important for real applications, where patient profiles contain more comphrehensive medical histories."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains.query_constructor.base import AttributeInfo\n",
    "from langchain.retrievers.self_query.base import SelfQueryRetriever\n",
    "\n",
    "metadata_field_info = [\n",
    "    AttributeInfo(\n",
    "        name=\"disease_category\",\n",
    "        description=\"Defines the disease group of patients related to this trial. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        # description=\"The trial is for patients when their disease is related to this category. One of ['cancer', 'leukemia', 'mental_health']\",\n",
    "        type=\"string\",\n",
    "    ),\n",
    "    AttributeInfo(\n",
    "        name=\"drugs\",\n",
    "        description=\"List of drug names used in the trial\",\n",
    "        type=\"str\",\n",
    "    ),    \n",
    "]\n",
    "\n",
    "document_content_description = \"The list of patient conditions to include or exclude them from the trial\"\n",
    "retriever_trial_sq = SelfQueryRetriever.from_llm(\n",
    "    model,\n",
    "    vectorstore_trials,\n",
    "    # vectorstore_trials_mpnet,\n",
    "    document_content_description,\n",
    "    metadata_field_info\n",
    "    # enable_limit=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'disease_category': 'leukemia', 'diseases': \"['relapsed or refractory acute myeloid leukemia (aml)', 'untreated aml', 'other idh1-mutated positive hematologic malignancies', 'myelodysplastic syndromes']\", 'drugs': \"['ag-120']\", 'nctid': 'NCT02074839', 'status': 'recruiting'}\n",
      "\n",
      "        Key Inclusion Criteria:\n",
      "\n",
      "          -  Subject must be ≥18 years of age.\n",
      "\n",
      "          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\n",
      "             based on local or central evaluation.\n",
      "\n",
      "          -  Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling,\n",
      "             and urine sampling during the study.\n",
      "\n",
      "          -  Subjects must have ECOG PS of 0 to 2.\n",
      "\n",
      "          -  Platelet count ≥20,000/µL (Transfusions to achieve this level are allowed).\n",
      "\n",
      "          -  Subjects must have adequate hepatic function as evidenced by: Aspartate\n",
      "             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)\n",
      "             ≤3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ≤1.5 x\n",
      "             upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic\n",
      "             disease\n",
      "\n",
      "          -  Subjects must have adequate renal function as evidenced by a serum creatinine ≤2.0 ×\n",
      "             ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration\n",
      "             rate (GFR)\n",
      "\n",
      "          -  Subjects must be recovered from any clinically relevant toxic effects of any prior\n",
      "             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\n",
      "\n",
      "          -  Female subjects with reproductive potential must have a negative serum pregnancy test\n",
      "             within 7 days prior to the start of therapy and on the first day of study drug\n",
      "             administration.\n",
      "\n",
      "        Key Exclusion Criteria:\n",
      "\n",
      "          -  Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days\n",
      "             of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the\n",
      "             time of screening, or with clinically significant graft-versus-host disease (GVHD).\n",
      "             (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin\n",
      "             GVHD is permitted.)\n",
      "\n",
      "          -  Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to\n",
      "             their first day of study drug administration. (Hydroxyurea is allowed prior to\n",
      "             enrollment and after the start of AG-120).\n",
      "\n",
      "          -  Subjects who received an investigational agent <14 days prior to their first day of\n",
      "             study drug administration.\n",
      "\n",
      "          -  Subjects who are pregnant or breastfeeding.\n",
      "\n",
      "          -  Subjects with an active severe infection or with an unexplained fever >38.5°C during\n",
      "             screening visits or on their first day of study drug administration (at the discretion\n",
      "             of the Investigator, subjects with tumor fever may be enrolled).\n",
      "\n",
      "          -  Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\n",
      "             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\n",
      "             within approximately 28 days of C1D1.\n",
      "\n",
      "          -  Subjects with a history of myocardial infarction within the last 6 months of\n",
      "             screening.\n",
      "\n",
      "          -  Subjects with a known unstable or uncontrolled angina pectoris.\n",
      "\n",
      "          -  Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\n",
      "\n",
      "          -  Subjects with known unstable or uncontrolled angina pectoris.\n",
      "\n",
      "          -  Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that\n",
      "             increase the risk of QT prolongation or arrhythmic events.\n",
      "\n",
      "          -  Patients taking medications that are known to prolong the QT interval\n",
      "\n",
      "          -  Subjects with known infection with human immunodeficiency virus (HIV) or active\n",
      "             hepatitis B or C.\n",
      "\n",
      "          -  Subjects with clinical symptoms suggesting active central nervous system (CNS)\n",
      "             leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if\n",
      "             there is a clinical suspicion of CNS involvement by leukemia during screening.\n",
      "\n",
      "          -  Subjects with immediately life-threatening, severe complications of leukemia such as\n",
      "             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\n",
      "             intravascular coagulation.\n",
      "      \n"
     ]
    }
   ],
   "source": [
    "# sample trial retrieval\n",
    "question = f\"\"\"\n",
    "Which trials are relevant to the patient with the following medical history?\\n\n",
    "patient_profile: {patient_profile}\n",
    "\"\"\"        \n",
    "docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "print(docs_retrieved[0].metadata)\n",
    "print(docs_retrieved[0].page_content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Trial Grader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "class grade(BaseModel):\n",
    "        \"\"\"The result of the trial's relevance check as relevance score and explanation.\"\"\"\n",
    "\n",
    "        relevance_score: str        \n",
    "        explanation: str = Field(description=\"Reasons to the given relevance score.\")        \n",
    "        further_information: str\n",
    "\n",
    "prompt_grader = PromptTemplate(\n",
    "        template=\"\"\" \n",
    "        You are a Principal Investigator (PI) for evaluating patients for clinical trials.\\n\n",
    "        Your task is to evaluate the relevance of a clinical trial to the given patient's medical profile. \\n\n",
    "        \n",
    "        \n",
    "        The clinical trial is related to these diseases: {trial_diseases} \\n\n",
    "        Here are the inclusion and exclusion criteria of the trial: \\n\\n {document} \\n\\n\n",
    "        \n",
    "        ===============                \n",
    "        Use the following steps to determine relevance and provide the necessary fields in your response: \\n\n",
    "        1- If the patient's profile meets any exclusion criteria, then the trial is not relevant --> relevance_score = 'No'. \\n\n",
    "        2- If the patient has or had the trial's inclusion diseases, then it is relevant --> relevance_score = 'Yes'.\\n        \n",
    "        3- If the patient did not have the trial's inclusion diseases, then it is not relevant --> relevance_score = 'No'.\\n\n",
    "                       \n",
    "        Example 1: \n",
    "The patient has Arthritis and the trial is related to pancreatic cancer. --> relevance_score = 'No' \\n\n",
    "        \n",
    "        Example 2: \n",
    "The patient has pancreatic cancer and the trial is also related to carcinoma pancreatic cancer. --> relevance_score = 'Yes' \\n\n",
    "\n",
    "        Example 3: \n",
    "The patient has pancreatic cancer and the trial is related to breast cancer or ovarian cancer. --> relevance_score = 'No'. \\n \n",
    "\n",
    "        Bring your justification in the explanation. \\n\n",
    "\n",
    "        Mention further information that is needed from the patient's medical history related to the trial's criteria \\n\n",
    "\n",
    "        ===============\n",
    "        Here is the patient's medical profile: {patient_profile} \\n\\n\n",
    "        \"\"\",\n",
    "        input_variables=[\"document\", \"patient_profile\", \"trial_diseases\"],\n",
    "    )\n",
    "\n",
    "llm_with_tool = model.with_structured_output(grade)\n",
    "retrieval_grader = prompt_grader | llm_with_tool"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('relevance_score', 'Yes')\n",
      "( 'explanation',\n",
      "  'The patient has a history of lymphoblastic leukemia, which falls under the '\n",
      "  'category of hematologic malignancies. The clinical trial is specifically '\n",
      "  'targeting IDH1-mutated hematologic malignancies, which aligns with the '\n",
      "  \"patient's medical history. Therefore, the trial is relevant based on the \"\n",
      "  \"patient's medical profile.\")\n",
      "( 'further_information',\n",
      "  'Additional information needed: 1. Confirmation of IDH1 R132 gene mutation '\n",
      "  \"in the patient's advanced hematologic malignancy. 2. Current platelet count \"\n",
      "  \"of the patient. 3. Details on the patient's hepatic and renal function \"\n",
      "  'tests. 4. Information on any recent surgeries, radiotherapy, or cancer '\n",
      "  'treatments. 5. Confirmation of negative pregnancy test for female patients '\n",
      "  'with reproductive potential.')\n"
     ]
    }
   ],
   "source": [
    "doc = docs_retrieved[0]\n",
    "doc_txt = doc.page_content\n",
    "trial_diseases = doc.metadata.get(\"diseases\")\n",
    "trial_score = retrieval_grader.invoke({\"patient_profile\": patient_profile, \"document\": doc_txt, \"trial_diseases\": trial_diseases})\n",
    "\n",
    "for score in trial_score:\n",
    "    nprint(score)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Hallucination Grader\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Yes\n",
      "('The patient has a history of lymphoblastic leukemia, which falls under the '\n",
      " 'category of hematologic malignancies. The clinical trial is specifically '\n",
      " 'targeting IDH1-mutated hematologic malignancies, which aligns with the '\n",
      " \"patient's medical history. Therefore, the trial is relevant based on the \"\n",
      " \"patient's medical profile.\")\n",
      "yes\n",
      "(\"The LLM's generated answer is grounded in the patient's medical profile. The \"\n",
      " 'patient has a history of lymphoblastic leukemia, and the clinical trial '\n",
      " 'mentioned targets IDH1-mutated hematologic malignancies, which aligns with '\n",
      " \"the patient's medical history.\")\n"
     ]
    }
   ],
   "source": [
    "class GradeHallucinations(BaseModel):\n",
    "    \"\"\"Binary score and explanation for whether the LLM's generated answer is grounded in / supported by the facts in the patient's medical profile.\"\"\"\n",
    "    # \"\"\"Binary score for hallucination present in generation answer.\"\"\"\n",
    "\n",
    "\n",
    "    binary_score: str = Field(\n",
    "        description=\"Answer is grounded in the patient's medical profile, 'yes' or 'no'\"\n",
    "    )\n",
    "    Reason: str = Field(description=\"Reasons to the given relevance score.\")\n",
    "\n",
    "\n",
    "# LLM with function call\n",
    "llm_with_tool = model.with_structured_output(GradeHallucinations)\n",
    "\n",
    "# Prompt\n",
    "system = \"\"\"You are a grader assessing whether an LLM generation is grounded in / supported by the facts in the patient's medical profile. \\n \n",
    "     Give a binary score 'yes' or 'no'. 'Yes' means that the answer is grounded in / supported by the facts in the patient's medical profile.\"\"\"\n",
    "hallucination_prompt = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\"system\", system),\n",
    "        (\"human\", \"Patient's medical profile: \\n\\n {patient_profile} \\n\\n LLM generation: {explanation}\"),\n",
    "    ]\n",
    ")\n",
    "\n",
    "hallucination_grader = hallucination_prompt | llm_with_tool\n",
    "print(trial_score.relevance_score)\n",
    "explanation = trial_score.explanation\n",
    "nprint(explanation)\n",
    "# docs = patient_profile\n",
    "score = hallucination_grader.invoke({\"patient_profile\": patient_profile, \"explanation\": explanation})\n",
    "grade = score.binary_score\n",
    "print(grade)\n",
    "nprint(score.Reason)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Profile Rewriter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'The patient is a 69-year-old with a medical history of lymphoblastic leukemia. They have participated in a trial with the identifier NCT06562807, which is currently ongoing.\\nSuggested relevant trials:\\n- leukemia: lymphoblastic leukemia is a type of leukemia, so the patient may benefit from trials related to leukemia.'"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "system = \"\"\"\n",
    "A trial cross match resulted in no trials for the patient.\n",
    "As a clinical specialist write a medical profile for this patient and see if their disease(s) can be relevant to any of these categories of mental_health, cancer, or leukemia.\n",
    "If yes, then suggest relevant medical trial categories for the agent.\n",
    "If no, then do not add anything there.\n",
    "\n",
    "Your output must be as below:\n",
    "<a text summart of original profile>\n",
    "Suggested relevant trials:\n",
    "<bullet points of relevant medical trial categoriyes from the above with a one line reason>\n",
    "\n",
    "Only include categories which can be related to patient diseases in more often cases.\n",
    "Disregard categories which ocasionaly or in some cases can be relevant to patient diseases.\n",
    "\n",
    "example:\n",
    "The patient is a X-year-old with a medical history of Y. They have participated ........  previous trials, and their trial status and completion date .........\n",
    "Suggested relevant trials:\n",
    "category X: [patient's disease] can be related to X due to Y.\n",
    "\"\"\"\n",
    "re_write_prompt = ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\"system\", system),\n",
    "        (\n",
    "            \"human\",\n",
    "            \"Here is a patient data:\\n\\n {patient_data} \\n write a patient profile.\",\n",
    "        ),\n",
    "    ]\n",
    ")\n",
    "\n",
    "profile_rewriter_chain = re_write_prompt | model | StrOutputParser()\n",
    "profile_rewriter_chain.invoke({\"patient_data\": patient_data})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Graph"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## State"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List\n",
    "from typing_extensions import TypedDict\n",
    "from langgraph.graph.message import AnyMessage, add_messages\n",
    "from langchain_core.messages import AIMessage, SystemMessage, HumanMessage, ToolMessage\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    # messages: Annotated[Sequence[BaseMessage], operator.add]\n",
    "    last_node: str\n",
    "    patient_prompt: str\n",
    "    patient_id: int\n",
    "    patient_data: dict\n",
    "    patient_profile: str\n",
    "    policy_eligible: bool\n",
    "    policies: List[Document]\n",
    "    checked_policy: Document\n",
    "    unchecked_policies: List[Document]\n",
    "    policy_qs: str\n",
    "    rejection_reason: str    \n",
    "    revision_number: int\n",
    "    max_revisions: int\n",
    "    trial_searches: int\n",
    "    max_trial_searches: int            \n",
    "    trials: List[Document]\n",
    "    relevant_trials: list[dict]\n",
    "    ask_expert: str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Agent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langgraph.checkpoint.sqlite import SqliteSaver\n",
    "from langgraph.prebuilt import ToolNode\n",
    "from langgraph.prebuilt import tools_condition\n",
    "from langchain_core.pydantic_v1 import BaseModel, Field\n",
    "from operator import itemgetter\n",
    "from typing import Literal\n",
    "from langgraph.graph import StateGraph, END\n",
    "\n",
    "\n",
    "model = ChatOpenAI(model=\"gpt-3.5-turbo\")  #reduce inference cost\n",
    "\n",
    "memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "\n",
    "class Patient_ID(BaseModel):\n",
    "    patient_id: int\n",
    "    # no_id: bool\n",
    "\n",
    "def patient_collector_node(state: AgentState):\n",
    "    patient_data_prompt = \"\"\"You are a helpful assistance in extrcting patient's medical history.\n",
    "Based on the following request identify and return the patient's ID number.\n",
    "\"\"\"\n",
    "\n",
    "    response = model.with_structured_output(Patient_ID).invoke([\n",
    "        SystemMessage(content=patient_data_prompt),\n",
    "        HumanMessage(content=state['patient_prompt'])\n",
    "    ])\n",
    "    patient_id = response.patient_id\n",
    "    # print(response)\n",
    "    print(f\"Patient ID: {patient_id}\")\n",
    "    patient_data = get_patient_data(patient_id)\n",
    "    print(patient_data)\n",
    "    if patient_data is not None:        \n",
    "        if patient_data.get('name'):\n",
    "            del patient_data['patient_id']\n",
    "            del patient_data['name']\n",
    "        patient_profile = chain_profile.invoke({'patient_data': patient_data})\n",
    "\n",
    "    return {\n",
    "        \"last_node\": \"patient_collector\",\n",
    "        \"patient_data\": patient_data,\n",
    "        \"patient_profile\": patient_profile,\n",
    "        \"patient_id\": patient_id,\n",
    "        \"revision_number\": state.get(\"revision_number\", 1) + 1,\n",
    "        'policy_eligible': 'N/A'\n",
    "        }\n",
    "\n",
    "def policy_search(state: AgentState) -> List[Document]:    \n",
    "    # question = f\"\"\"\n",
    "    # Does the following patient profile comply with the institutional policies?\\n\n",
    "    # {patient_profile}\n",
    "    # \"\"\"\n",
    "    docs_retrieved = retriever_policy.get_relevant_documents(patient_profile)    \n",
    "    return {\n",
    "        \"last_node\": \"policy_search\",\n",
    "        \"policies\": docs_retrieved,\n",
    "        \"unchecked_policies\": docs_retrieved.copy(),\n",
    "    }\n",
    "\n",
    "def policy_evaluator(state: AgentState, policy_doc: Document = None):\n",
    "    if policy_doc is None:\n",
    "        policy_doc = state['unchecked_policies'][0]\n",
    "    \n",
    "    policy_header = policy_doc.page_content.split('\\n', 2)[1]\n",
    "    print(f'Evaluating Policy:\\n {policy_header}')\n",
    "    \n",
    "    policy = policy_doc.page_content\n",
    "    \n",
    "    policy_qs = policy_rps_chain.invoke({\"policy\": policy})\n",
    "    \n",
    "    # result = policy_repl(policy_qs, state['patient_profile'])\n",
    "    result = policy_tools(policy_qs, state['patient_profile'])\n",
    "    # nprint(result['output'])\n",
    "\n",
    "    class eligibility(BaseModel):\n",
    "        \"\"\" Give the patient's eligibility result.\"\"\"\n",
    "\n",
    "        eligibility: str = Field(description=\"Patient's eligibility for the clinical trial. 'yes' or 'no'\")\n",
    "        reason: str = Field(description=\"The reason(s) only if the patient is not eligible for clinical trials. Othereise use N/A\")\n",
    "\n",
    "        class Config:\n",
    "            schema_extra = {\n",
    "                \"example\": {\n",
    "                    \"eligibility\": 'yes',\n",
    "                    \"reason\": \"N/A\",\n",
    "                },\n",
    "                \"example 2\": {\n",
    "                    \"eligibility\": 'no',\n",
    "                    \"reason\": \"The patient is pregnant at the moment.\",\n",
    "                },                \n",
    "            }\n",
    "\n",
    "    llm_with_tools = model.bind_tools([eligibility])\n",
    "    message = f\"\"\"Evaluation of the patient's eligibility:\n",
    "    {result}\\n\\n\n",
    "    Is the patient eligible according to this policy?\"\"\"\n",
    "    response = llm_with_tools.invoke(message)\n",
    "            \n",
    "    state[\"policy_eligible\"] = response.tool_calls[0]['args']['eligibility'] == 'yes'\n",
    "    state[\"rejection_reason\"] = response.tool_calls[0]['args']['reason']\n",
    "    \n",
    "    # remove the first element of unchecked_policies\n",
    "    state['unchecked_policies'].pop(0)\n",
    "    state[\"revision_number\"] = state.get(\"revision_number\", 1) + 1\n",
    "    state['checked_policy'] = policy_doc\n",
    "    state['policy_qs'] = policy_qs\n",
    "    state['last_node'] = 'policy_evaluator'\n",
    "\n",
    "    return state\n",
    "\n",
    "def trial_search(state: AgentState):\n",
    "    \"\"\"\n",
    "    This node searches the trial database to retrieve a list of clinical trials that match the patient's medical history.\n",
    "    \"\"\"\n",
    "\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    question = f\"\"\"\n",
    "    Which trials are relevant to the patient with the following medical history?\\n\n",
    "    patient_profile: {patient_profile}\n",
    "    \"\"\"        \n",
    "    docs_retrieved = retriever_trial_sq.get_relevant_documents(question)\n",
    "    # print(state)\n",
    "    trial_searches = state.get('trial_searches') or 0\n",
    "    return {\n",
    "        'last_node': 'trial_search',\n",
    "        'trials': docs_retrieved,\n",
    "        'trial_searches': trial_searches + 1,\n",
    "        }\n",
    "\n",
    "def grade_trials(state: AgentState, trials: List[Document] = None):\n",
    "    \"\"\"\n",
    "    Determines whether the retrieved documents are relevant to the question.\n",
    "\n",
    "    Args:\n",
    "        state (dict): The current graph state\n",
    "\n",
    "    Returns:\n",
    "        state (dict): Updates documents key with only filtered relevant documents\n",
    "    \"\"\"\n",
    "\n",
    "    print(\"----- CHECKING THE TRIALS RELEVANCE TO PATIENT PROFILE ----- \")\n",
    "    \n",
    "    if trials is None:\n",
    "        trials = state['trials']\n",
    "    patient_profile = state['patient_profile']\n",
    "\n",
    "    # Score each doc\n",
    "    relevant_trials = []\n",
    "    for trial in trials:\n",
    "        doc_txt = trial.page_content\n",
    "        trial_diseases = trial.metadata['diseases']\n",
    "        nctid = trial.metadata['nctid']\n",
    "        print(f\"---GRADER: TRIAL {nctid}: ---\") \n",
    "        trial_score = retrieval_grader.invoke(\n",
    "            {\n",
    "                \"patient_profile\": patient_profile, \n",
    "                \"document\": doc_txt, \n",
    "                \"trial_diseases\": trial_diseases\n",
    "            }\n",
    "        )\n",
    "            \n",
    "        relevance_score = trial_score.relevance_score\n",
    "        trial_score_dic = dict(trial_score)\n",
    "        trial_score_dic['nctid'] = nctid                    \n",
    "\n",
    "        if relevance_score.lower() == \"yes\":   \n",
    "            # Hullucination check         \n",
    "            explanation = trial_score.explanation            \n",
    "            factual_score = hallucination_grader.invoke({\"patient_profile\": patient_profile, \"explanation\": explanation})\n",
    "            factual_score_grade = factual_score.binary_score            \n",
    "            if factual_score_grade == \"no\":\n",
    "                print(\"--- HALLUCINATION: MODEL'S EXPLANATION IS NOT GROUNDED IN PATIENT PROFILE --> REJECTED---\")\n",
    "                trial_score_dic['relevance_score'] = 'no'\n",
    "                trial_score_dic['explanation'] = \"Agent's Hallucination\"\n",
    "\n",
    "        if relevance_score.lower() == \"yes\" and factual_score_grade == \"yes\":\n",
    "            print(f\"---TRIAL RELEVANT---\")                        \n",
    "        else:\n",
    "            print(f\"--- TRIAL NOT RELEVANT---\")\n",
    "\n",
    "        relevant_trials.append(trial_score_dic)\n",
    "        \n",
    "    return {\n",
    "        'last_node': 'grade_trials',\n",
    "        \"relevant_trials\": relevant_trials\n",
    "        }\n",
    "\n",
    "def profile_rewriter(state: AgentState):\n",
    "    patient_data = state['patient_data']\n",
    "    patient_profile_rewriten = profile_rewriter_chain.invoke({\"patient_data\": patient_data})\n",
    "    # print in capitals\n",
    "    print(\"--- PROFILE REWRITER: PATIENT'S PROFILE REWRITEN ---\")\n",
    "    # state['patient_profile'] = patient_profile_rewriten\n",
    "    return {\n",
    "        'last_node': 'profile_rewriter',\n",
    "        'patient_profile': patient_profile_rewriten\n",
    "    }\n",
    "    \n",
    "\n",
    "# ========= continue functions =========\n",
    "def should_continue_patient(state: AgentState):\n",
    "    # end = False\n",
    "    if state.get(\"patient_data\"):\n",
    "        # print('patient data found')\n",
    "        print(state.get(\"patient_profile\", 'No profile generated'))\n",
    "        return \"policy_search\"\n",
    "    else:\n",
    "        print('Patient data not found in the database')\n",
    "        return END\n",
    "        \n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')\n",
    "        # print(state.get(\"patient_data\", 1))\n",
    "        return END        \n",
    "\n",
    "def should_continue_policy(state: AgentState):\n",
    "    if state[\"revision_number\"] > state[\"max_revisions\"]:\n",
    "        print('max revision reached')        \n",
    "        return END\n",
    "    more_policies = len(state[\"unchecked_policies\"]) > 0\n",
    "    if state[\"policy_eligible\"]:\n",
    "        if more_policies:\n",
    "            print(\"-------------- Check the next policy --------------\")\n",
    "            return \"policy_evaluator\"\n",
    "        else:\n",
    "            print(\"-------------- Patient passed the general trials policies --------------\")\n",
    "            return \"trial_search\"\n",
    "    else:\n",
    "        print(\"Patient did not pass this policy.\\n\")\n",
    "        print(state['checked_policy'].page_content)\n",
    "        # print(\"Patient did not pass the general trials policies.\\n\")        \n",
    "        print('Rejection Reason: ')\n",
    "        nprint(state['rejection_reason'])\n",
    "        print(\"You can correct the patient's medical profile if required.\")        \n",
    "        return END\n",
    "\n",
    "def should_continue_trials(state: AgentState):\n",
    "    relevant_trials = state[\"relevant_trials\"]    \n",
    "    has_relevant_trial = any(trial['relevance_score'] == 'Yes' for trial in state[\"relevant_trials\"])\n",
    "\n",
    "    if state[\"trial_searches\"] > state[\"max_trial_searches\"]:\n",
    "        print('max trial searches reached')\n",
    "        next = END    \n",
    "    # elif not state[\"relevant_trials\"]:\n",
    "    elif has_relevant_trial == False:\n",
    "        print('----- No relevant trials found --> rewriting the patient profile -----')\n",
    "        next = \"profile_rewriter\"        \n",
    "    else:\n",
    "        next = END\n",
    "        print('to end')\n",
    "    return next\n",
    "\n",
    "\n",
    "# ==== define graph nodes====\n",
    "builder = StateGraph(AgentState)\n",
    "builder.set_entry_point(\"patient_collector\")\n",
    "builder.add_node(\"patient_collector\", patient_collector_node)\n",
    "builder.add_node(\"policy_search\", policy_search)\n",
    "builder.add_node(\"policy_evaluator\", policy_evaluator)\n",
    "builder.add_node(\"trial_search\", trial_search)\n",
    "builder.add_node(\"grade_trials\", grade_trials)\n",
    "builder.add_node(\"profile_rewriter\", profile_rewriter)\n",
    "\n",
    "# ===== define graph edges====\n",
    "builder.add_conditional_edges(\n",
    "    \"patient_collector\", \n",
    "    should_continue_patient, \n",
    "    {END: END    \n",
    "    ,\"policy_search\": \"policy_search\"\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"policy_evaluator\", \n",
    "    should_continue_policy, \n",
    "    {\n",
    "    \"trial_search\": \"trial_search\"\n",
    "    , \"policy_evaluator\": \"policy_evaluator\"\n",
    "    , END: END\n",
    "    }\n",
    ")\n",
    "\n",
    "builder.add_edge(\"policy_search\", \"policy_evaluator\")\n",
    "builder.add_edge(\"trial_search\", \"grade_trials\")\n",
    "builder.add_edge(\"profile_rewriter\",\"trial_search\")\n",
    "# builder.set_finish_point(\"grade_trials\")\n",
    "\n",
    "builder.add_conditional_edges(\n",
    "    \"grade_trials\", \n",
    "    should_continue_trials, \n",
    "    {\n",
    "    \"profile_rewriter\": \"profile_rewriter\"    \n",
    "    , END: END\n",
    "    }\n",
    ")\n",
    "\n",
    "\n",
    "\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    ")\n",
    "\n",
    "from IPython.display import Image\n",
    "\n",
    "Image(graph.get_graph().draw_png())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Running with no gui and intrupts:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient ID: 2\n",
      "{'patient_id': 2, 'name': 'Alice Brown', 'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}\n",
      "Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.\n",
      "{'patient_collector': {'last_node': 'patient_collector', 'patient_id': 2, 'patient_data': {'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.', 'policy_eligible': 'N/A', 'revision_number': 2}}\n",
      "{'policy_search': {'last_node': 'policy_search', 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'unchecked_policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})]}}\n",
      "Evaluating Policy:\n",
      " #### 1. **General Eligibility Criteria**\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 2 eligible for any medical trial?', 'patient_id': 2, 'patient_data': {'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.', 'policy_eligible': True, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'policy_qs': \"1. Is the patient under 18 or over 75 years old?\\n2. Is the patient's gender restricted by the trial protocol?\\n3. Has the patient not provided informed consent?\\n4. Is the patient not a resident of the country where the trial is conducted?\\n5. Does the patient not have valid health insurance coverage?\", 'rejection_reason': 'N/A', 'revision_number': 3, 'max_revisions': 10, 'trial_searches': None, 'max_trial_searches': 3, 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy:\n",
      " #### 4. **Medication and Treatment Restrictions**\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 2 eligible for any medical trial?', 'patient_id': 2, 'patient_data': {'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.', 'policy_eligible': True, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'policy_qs': '1. Is the patient on any medication that could interfere with the study drug?\\n2. Does the patient have a history of substance abuse within the past 12 months?\\n3. Has the patient received live vaccines within 30 days prior to the start of the trial?', 'rejection_reason': 'N/A', 'revision_number': 4, 'max_revisions': 10, 'trial_searches': None, 'max_trial_searches': 3, 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy:\n",
      " #### 2. **Medical History Restrictions**\n",
      "-------------- Check the next policy --------------\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 2 eligible for any medical trial?', 'patient_id': 2, 'patient_data': {'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.', 'policy_eligible': True, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'policy_qs': '1. Does patient have severe heart disease (e.g., recent myocardial infarction, heart failure)?\\n2. Does patient have uncontrolled Diabetes Mellitus?\\n3. Has patient undergone major surgery within the current year?\\n4. Does patient have active tuberculosis, hepatitis B or C, or HIV?', 'rejection_reason': 'N/A', 'revision_number': 5, 'max_revisions': 10, 'trial_searches': None, 'max_trial_searches': 3, 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n",
      "Evaluating Policy:\n",
      " #### 3. **Previous Trial Participation**   \n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n",
      "Rejection Reason: \n",
      "'Currently enrolled in another active trial (NCT08008231)'\n",
      "You can correct the patient's medical profile if required.\n",
      "{'policy_evaluator': {'last_node': 'policy_evaluator', 'patient_prompt': 'Is patient 2 eligible for any medical trial?', 'patient_id': 2, 'patient_data': {'age': 70, 'medical_history': 'Anxiety', 'previous_trials': 'NCT08008231', 'trial_status': 'Ongoing', 'trial_completion_date': None}, 'patient_profile': 'Patient is a 70-year-old individual with a medical history of anxiety. They have previously participated in the clinical trial NCT08008231, which is currently ongoing. Given their history of anxiety, the patient may be suitable for clinical trials focusing on mental health or anxiety disorders.', 'policy_eligible': False, 'policies': [Document(page_content='\\n#### 1. **General Eligibility Criteria**\\n   - **Age Restrictions**: Patients must be between 18 and 75 years old.\\n   - **Gender**: No restrictions unless specified by the trial protocol.\\n   - **Informed Consent**: All patients must provide informed consent prior to participation.\\n   - **Residency**: Patients must be residents of the country where the trial is conducted.\\n   - **Health Insurance**: Patients must have valid health insurance coverage.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 4. **Medication and Treatment Restrictions**\\n   - **Concurrent Medications**: Patients must not be on any medication that could interfere with the study drug, unless specified by the trial protocol.\\n   - **Substance Abuse**: Patients with a history of substance abuse within the past 12 months are excluded.\\n   - **Vaccinations**: Patients must not have received live vaccines within 30 days prior to the start of the trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 2. **Medical History Restrictions**\\n   - **Severe Heart Disease** (e.g., recent myocardial infarction, heart failure)\\n   - **Uncontrolled Diabetes Mellitus**     \\n   - **Recent Surgeries**: Patients who have undergone major surgery within the current year are not eligible.   \\n   - **Infectious Diseases**: Patients with active tuberculosis, hepatitis B or C, or HIV are excluded unless the trial is specifically designed for these conditions.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'})], 'checked_policy': Document(page_content='\\n#### 3. **Previous Trial Participation**   \\n   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\\n   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\\n   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\\n   - **Trial Outcomes**:\\n     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\\n     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\\n', metadata={'source': '../../source_data/instut_trials_policy.md'}), 'unchecked_policies': [], 'policy_qs': '1. Has the patient participated in more than two clinical trials in the past year excluding this trial?\\n2. Is the patient currently enrolled in another active trial?\\n3. Has the patient participated in any other clinical trial within the past 5 months from now?\\n4. Was the patient withdrawn from previous trials due to adverse effects?\\n5. Has the patient completed a trial without a documented recovery period before participating in a new trial?', 'rejection_reason': 'Currently enrolled in another active trial (NCT08008231)', 'revision_number': 6, 'max_revisions': 10, 'trial_searches': None, 'max_trial_searches': 3, 'trials': None, 'relevant_trials': None, 'ask_expert': None}}\n"
     ]
    }
   ],
   "source": [
    "import langchain\n",
    "langchain.debug = False\n",
    "sample_patient_id = 2\n",
    "thread = {\"configurable\": {\"thread_id\": \"0\"}}\n",
    "events_gen = graph.stream({\n",
    "    'patient_prompt': f\"Is patient {sample_patient_id} eligible for any medical trial?\",    \n",
    "    \"max_revisions\": 10,\n",
    "    \"revision_number\": 1,\n",
    "    'max_trial_searches':3,\n",
    "}, thread)\n",
    "for event in events_gen:\n",
    "    print(event)\n",
    "# event = events_gen.__next__()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Application GUI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Closing server running on port: 7959\n",
      "Running on local URL:  http://127.0.0.1:7959\n",
      "\n",
      "To create a public link, set `share=True` in `launch()`.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div><iframe src=\"http://127.0.0.1:7959/\" width=\"100%\" height=\"500\" allow=\"autoplay; camera; microphone; clipboard-read; clipboard-write;\" frameborder=\"0\" allowfullscreen></iframe></div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient ID: 56\n",
      "{'patient_id': 56, 'name': 'James Thomas', 'age': 52, 'medical_history': 'Depression', 'previous_trials': None, 'trial_status': None, 'trial_completion_date': None}\n",
      "Patient is a 52-year-old individual with a history of Depression. There is no record of previous trial participation. Given the patient's medical history of Depression, they may be suitable for clinical trials focusing on new antidepressant medications or therapies for mental health conditions.\n",
      "Patient ID: 5\n",
      "{'patient_id': 5, 'name': 'John Davis', 'age': 40, 'medical_history': 'Hypertension', 'previous_trials': 'NCT09100764', 'trial_status': 'Withdrawn', 'trial_completion_date': '2023-10-24'}\n",
      "Patient X is a 40-year-old individual with a medical history of hypertension. They have previously participated in the clinical trial with the identifier NCT09100764, which was withdrawn before completion on October 24, 2023. Given their history of hypertension, the patient may be eligible for clinical trials related to cardiovascular health and hypertension management.\n",
      "patient_collector node\n",
      "Patient is a 76-year-old individual with a history of esophageal cancer. They have previously participated in the clinical trial NCT01098495, which is ongoing. Given their medical history of esophageal cancer, the patient may be eligible for clinical trials focusing on cancer treatments.\n",
      "State updated\n",
      "('policy_search',)\n",
      "Evaluating Policy:\n",
      " #### 2. **Medical History Restrictions**\n",
      "-------------- Check the next policy --------------\n",
      "Evaluating Policy:\n",
      " #### 3. **Previous Trial Participation**   \n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n",
      "Rejection Reason: \n",
      "'The patient is currently enrolled in another active trial.'\n",
      "You can correct the patient's medical profile if required.\n",
      "-------------- Check the next policy --------------\n",
      "State updated\n",
      "('policy_evaluator',)\n",
      "Evaluating Policy:\n",
      " #### 3. **Previous Trial Participation**   \n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 3. **Previous Trial Participation**   \n",
      "   - **Trial Frequency**: Patients should not have participated in more than two clinical trials in the past year excluding this trial to prevent overexposure to experimental treatments.\n",
      "   - **Active Trials**: Patients currently enrolled in another active trial are not eligible until they have completed or withdrawn from the ongoing trial.\n",
      "   - **Recent Trials**: Patients cannot have participated in any other clinical trial within the past 5 months from now.\n",
      "   - **Trial Outcomes**:\n",
      "     - Patients who were withdrawn from previous trials due to adverse effects are not eligible.\n",
      "     - Patients who have completed a trial must have a documented recovery period before participating in a new trial.\n",
      "\n",
      "Rejection Reason: \n",
      "('The patient has participated in another clinical trial within the past 5 '\n",
      " 'months.')\n",
      "You can correct the patient's medical profile if required.\n",
      "-------------- Check the next policy --------------\n",
      "State updated\n",
      "('policy_evaluator',)\n",
      "Evaluating Policy:\n",
      " #### 4. **Medication and Treatment Restrictions**\n",
      "-------------- Check the next policy --------------\n",
      "Evaluating Policy:\n",
      " #### 6. **Special Considerations**\n",
      "-------------- Check the next policy --------------\n",
      "Evaluating Policy:\n",
      " #### 1. **General Eligibility Criteria**\n",
      "Patient did not pass this policy.\n",
      "\n",
      "\n",
      "#### 1. **General Eligibility Criteria**\n",
      "   - **Age Restrictions**: Patients must be between 18 and 75 years old.\n",
      "   - **Gender**: No restrictions unless specified by the trial protocol.\n",
      "   - **Informed Consent**: All patients must provide informed consent prior to participation.\n",
      "   - **Residency**: Patients must be residents of the country where the trial is conducted.\n",
      "   - **Health Insurance**: Patients must have valid health insurance coverage.\n",
      "\n",
      "Rejection Reason: \n",
      "'The patient is over 75 years old.'\n",
      "You can correct the patient's medical profile if required.\n",
      "-------------- Patient passed the general trials policies --------------\n",
      "State updated\n",
      "('trial_search',)\n"
     ]
    }
   ],
   "source": [
    "from helper_gui import trials_gui\n",
    "\n",
    "memory = SqliteSaver.from_conn_string(\":memory:\")\n",
    "graph = builder.compile(\n",
    "    checkpointer=memory\n",
    "    , interrupt_after=['patient_collector', 'policy_search', 'trial_search', 'grade_trials', 'profile_rewriter']\n",
    "    # , interrupt_after=['grade_trials','profile_rewriter']\n",
    ")\n",
    "\n",
    "try:\n",
    "    app.demo.close()\n",
    "except:\n",
    "    print('initial run')\n",
    "app = trials_gui(graph)    \n",
    "app.demo.launch(server_name=\"127.0.0.1\", server_port=7959)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Possible Further Improvements for Real Application:\n",
    "\n",
    "To enhance the robustness of the pipeline and effectively manage diverse patient and trial conditions, it is essential to implement advanced methodologies, particularly when handling large databases of patients, trials, and policies.\n",
    "\n",
    "Recommended Improvements:\n",
    "1. Graph-Based Retrieval-Augmented Generation (RAG):\n",
    "- Implement graph-based RAG to focus on the relationships between entities across different databases. For instance, map connections between patients, diseases, drugs, and trials to provide more accurate and relevant information retrieval.\n",
    "\n",
    "2. Advanced RAG pipeline:\n",
    "- The output of RAG pipelines can be improved by benefiting from more advanced techniques such as Adaptive RAG, Corrective RAG, and Self-RAG. Such pipelines are more robust againts hallucinations and wrong inferences in LLMs outputs.\n",
    "\n",
    "4. Advanced Chain of Thought Processing:\n",
    "- Employ a more sophisticated chain of thought process to cross-match the patient's profile with the detailed information provided in each trial or policy. This approach enhances the decision-making capability of the system by considering multiple factors simultaneously.\n",
    "\n",
    "1. Fine-Tuning the Large Language Model:\n",
    "- Fine-tune the large language model using a diverse set of medical trial data to improve the accuracy and relevance of its inferences. This customization ensures the model better understands the nuances and specifics of clinical trial data.\n",
    "\n",
    "1. Cyclic Graphs for Iterative Evaluation:\n",
    "- Utilize cyclic graphs to iteratively evaluate the patient's profile against various trials and policies. This iterative approach allows the system to refine its matches through multiple rounds of evaluation, ultimately identifying the best possible trial for the patient."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".llmenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
